Identification

Name
Cyclosporine
Accession Number
DB00091  (BTD00003, BIOD00003)
Type
Small Molecule
Groups
Approved, Investigational, Vet Approved
Description

A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. Cyclosporine is produced as a metabolite by the fungus species Cordyceps militaris. (From Martindale, The Extra Pharmacopoeia, 30th ed).

Structure
Thumb
Synonyms
  • Ciclosporin
  • Ciclosporina
  • Ciclosporine
  • Ciclosporinum
  • CsA
  • CyA
  • Cyclosporin
  • Cyclosporin A
External IDs
27-400 / Antibiotic S 7481F1 / Antibiotic S-7481F1 / NSC-290193 / OL-27-400 / SANG-35 / SDZ-OXL-400
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclosporineCapsule25 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
NeoralCapsule, liquid filled25 mg/1OralNovartis1995-07-14Not applicableUs
NeoralCapsule, liquid filled25 mg/1OralCardinal Health1995-07-14Not applicableUs
NeoralCapsule, liquid filled100 mg/1OralNovartis1995-07-14Not applicableUs
NeoralSolution100 mg/mLOralNovartis1995-07-14Not applicableUs
Neoral 100mgCapsule100 mgOralNovartis1995-12-31Not applicableCanada
Neoral 10mgCapsule10 mgOralNovartis1998-10-02Not applicableCanada
Neoral 25mgCapsule25 mgOralNovartis1995-12-31Not applicableCanada
Neoral 50mgCapsule50 mgOralNovartis1995-12-31Not applicableCanada
Neoral Oral Solution 100mg/mlSolution100 mgOralNovartis1995-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cyclosporine Oral SolutionSolution100 mgOralApotex Corporation2002-07-30Not applicableCanada
CyclosporineCapsule, gelatin coated25 mg/1OralApotex Corporation2002-05-29Not applicableUs
CyclosporineCapsule25 mg/1OralEon Labs, Inc.2000-01-13Not applicableUs
CyclosporineCapsule, gelatin coated100 mg/1OralAmerincan Health Packaging2015-03-30Not applicableUs
CycloSPORINECapsule, liquid filled25 mg/1OralActavis Pharma Company2008-12-01Not applicableUs
CyclosporineSolution100 mg/mLOralMorton Grove Pharmaceuticals, Inc.2005-02-092017-10-21Us
CyclosporineSolution100 mg/mLOralIVAX Pharmaceuticals, Inc.2005-03-29Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralMayne Pharma2016-07-18Not applicableUs
CyclosporineCapsule, liquid filled100 mg/1OralPhysicians Total Care, Inc.2006-02-10Not applicableUs
CyclosporineCapsule, gelatin coated100 mg/1OralApotex Corporation2002-05-29Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aqua-stasisLiquid.0005 g/100mLOphthalmicDr Marc's Manufacturing And Sales2016-02-23Not applicableUs
Cyclo-dermLiquid.25 g/100mLTopicalDr Marc's Manufacturing And Sales2016-02-23Not applicableUs
Hydro-stasisLiquid.0005 g/100mLOphthalmicDr Marc's Manufacturing And Sales2016-02-23Not applicableUs
Nail Cyclosporin-ALiquid.25 g/100mLTopicalDr Marc's Manufacturing And Sales2016-02-23Not applicableUs
International/Other Brands
Sangcya
Categories
UNII
83HN0GTJ6D
CAS number
59865-13-3
Weight
Average: 1202.635
Monoisotopic: 1201.841368058
Chemical Formula
C62H111N11O12
InChI Key
PMATZTZNYRCHOR-CGLBZJNRSA-N
InChI
InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1
IUPAC Name
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R,4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone
SMILES
CC[[email protected]@H]1NC(=O)[[email protected]]([[email protected]](O)[[email protected]](C)C\C=C\C)N(C)C(=O)[[email protected]](C(C)C)N(C)C(=O)[[email protected]](CC(C)C)N(C)C(=O)[[email protected]](CC(C)C)N(C)C(=O)[[email protected]@H](C)NC(=O)[[email protected]](C)NC(=O)[[email protected]](CC(C)C)N(C)C(=O)[[email protected]@H](NC(=O)[[email protected]](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C

Pharmacology

Indication

For treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis.

Structured Indications
Pharmacodynamics

Used in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited. The T1-helper cell is the main target, although the T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits lymphokine production and release including interleukin-2.

Mechanism of action

Cyclosporine binds to cyclophilin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production and interleukin release. In ophthalmic applications, the precise mechanism of action is not known. Cyclosporine emulsion is thought to act as a partial immunomodulator in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.

TargetActionsOrganism
ACalcium signal-modulating cyclophilin ligand
binder
Human
ACalcineurin subunit B type 2
inhibitor
Human
UPeptidyl-prolyl cis-trans isomerase ANot AvailableHuman
UPeptidyl-prolyl cis-trans isomerase F, mitochondrial
binder
Human
Absorption

The absorption of cyclosporine from the gastrointestinal tract is incomplete and variable. The extent of absorption is dependent on the individual patient, the patient population, and the formulation. The absolute bioavailability of cyclosproine administered as Sandimmune® is dependent on the patient population, estimated to be less than 10% in liver transplant patients and as great as 89% in some renal transplant patients. Compared to an intravenous infusion, the absolute bioavailability of the oral solution is approximately 30% based upon the results in 2 patients. The cyclosporine capsules and oral solution are bioequivalent. The time of peak blood concentrations (Tmax) following oral administration of cyclosporine [modified] ranged from 1.5 - 2.0 hours.

Volume of distribution

The steady state volume of distribution during intravenous dosing has been reported as 3 to 5 L/kg in solid organ transplant recipients. Cyclosporine is excreted in human milk.

Protein binding

In the plasma, approximately 90% is bound to proteins, primarily lipoproteins. In blood, the distribution is concentration dependent. Approximately 33% to 47% is in plasma, 4% to 9% in lymphocytes, 5% to 12% in granulocytes, and 41% to 58% in erythrocytes.

Metabolism

Hepatic, extensively metabolized by the cytochrome P450 3A enzyme system in the liver. It is also metabolized in the gastrointestinal tract and kidney to a lesser degree. The metabolites are significantly less potent than the parent compound. The major metabolites (M1, M9, and M4N) result from oxidation at the 1-beta, 9-gamma, and 4-N-demethylated positions, respectively.

Route of elimination

Elimination is primarily biliary with only 6% of the dose (parent drug and metabolites) excreted in the urine. Only 0.1% of the dose is excreted in the urine as unchanged drug.

Half life

Biphasic and variable, approximately 7 hours (range 7 to 19 hours) in children and approximately 19 hours (range 10 to 27 hours) in adults.

Clearance

Following intravenous administration, the blood clearance of cyclosporine (assay: HPLC) is approximately 5 to 7 mL/min/kg in adult recipients of renal or liver allografts. Blood cyclosporine clearance appears to be slightly slower in cardiac transplant patients. The following are clearance parameters (CL/F) for select patient populations: * 593 ± 204 mL/min [De novo renal transplant patients, 597±174 mg/day] * 492 ± 140 mL/min [Stable renal transplant patients, 344±122 mg/day] * 577 ± 309 mL/min [De novo liver transplant, 458±190 mg/day] * 613 ± 196 mL/min [De novo rheumatoid arthritis, 182±55.6 mg/day] * 723 ± 186 mL/min [De novo psoriasis, 189±69.8 mg/day]
* 285 ± 94 mL/min [Stable Liver Transplant, Age 2 - 8, Dosed T.I.D 101±25 mg/day] * 378 ± 80 mL/min [Stable Liver Transplant, Age 8 - 15, Dosed B.I.D 188±55 mg/day]
* 171 mL/min [Stable liver transplant, Age 3, Dosed B.I.D 120 mg/day] * 328 ± 121 mL/min [Stable liver transplant, Age 8 - 15, Dosed B.I.D 158±55 mg/day]
* 418 ± 143 mL/min [Stable renal transplant, Age 7 - 15, Dosed B.I.D 328±83 mg/day]

Toxicity

The oral LD50 is 2329 mg/kg in mice, 1480 mg/kg in rats, and > 1000 mg/kg in rabbits. The I.V. LD50 is 148 mg/kg in mice, 104 mg/kg in rats, and 46 mg/kg in rabbits.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Cyclosporine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Cyclosporine can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe metabolism of Cyclosporine can be decreased when combined with 2-mercaptobenzothiazole.Vet Approved
3,4-DichloroisocoumarinThe serum concentration of Cyclosporine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Cyclosporine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Cyclosporine.Approved
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Cyclosporine.Approved
AceclofenacAceclofenac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
AcemetacinAcemetacin may increase the nephrotoxic activities of Cyclosporine.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Cyclosporine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Cyclosporine.Approved
AcetazolamideThe serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
AclarubicinAclarubicin may increase the nephrotoxic activities of Cyclosporine.Investigational
AdalimumabThe serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.Approved
AdapaleneAdapalene may increase the nephrotoxic activities of Cyclosporine.Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Cyclosporine.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Cyclosporine.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Cyclosporine.Approved, Vet Approved
AlclofenacAlclofenac may increase the nephrotoxic activities of Cyclosporine.Approved, Withdrawn
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Cyclosporine.Approved
AlcuroniumCyclosporine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Cyclosporine.Approved, Illicit
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Cyclosporine.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Cyclosporine.Approved
AlminoprofenAlminoprofen may increase the nephrotoxic activities of Cyclosporine.Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Cyclosporine.Approved, Investigational
AlogliptinThe serum concentration of Cyclosporine can be increased when it is combined with Alogliptin.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Cyclosporine.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Cyclosporine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Cyclosporine.Approved, Illicit, Investigational
Aluminium clofibrateCyclosporine may increase the nephrotoxic activities of Aluminium clofibrate.Experimental
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Cyclosporine.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Cyclosporine.Approved, Investigational
AmikacinAmikacin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
AmilorideAmiloride may increase the hyperkalemic activities of Cyclosporine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Cyclosporine.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Cyclosporine.Approved
AmiodaroneThe metabolism of Cyclosporine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Cyclosporine.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Cyclosporine.Approved
AmobarbitalThe metabolism of Cyclosporine can be increased when combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Cyclosporine.Approved, Investigational
AmorolfineThe metabolism of Cyclosporine can be decreased when combined with Amorolfine.Approved, Investigational
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
AmprenavirThe serum concentration of Cyclosporine can be increased when it is combined with Amprenavir.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Amrinone.Approved
AmrubicinAmrubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
AndrographolideAndrographolide may increase the nephrotoxic activities of Cyclosporine.Investigational
AnidulafunginThe metabolism of Cyclosporine can be decreased when combined with Anidulafungin.Approved, Investigational
AnisodamineAnisodamine may increase the nephrotoxic activities of Cyclosporine.Investigational
annamycinannamycin may increase the nephrotoxic activities of Cyclosporine.Investigational
AntipyrineAntipyrine may increase the nephrotoxic activities of Cyclosporine.Approved
Antithrombin III humanThe serum concentration of Cyclosporine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Cyclosporine can be increased when it is combined with Apixaban.Approved
ApocyninApocynin may increase the nephrotoxic activities of Cyclosporine.Investigational
ApramycinApramycin may increase the nephrotoxic activities of Cyclosporine.Experimental, Vet Approved
ApremilastApremilast may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
AprepitantThe serum concentration of Cyclosporine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Cyclosporine can be increased when it is combined with Aprotinin.Approved, Withdrawn
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Cyclosporine.Experimental
ArbekacinArbekacin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Cyclosporine.Approved, Investigational
ArgatrobanThe serum concentration of Cyclosporine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Cyclosporine.Approved, Investigational
ArmodafinilThe serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Cyclosporine can be decreased when combined with Artemether.Approved
AsenapineThe metabolism of Asenapine can be decreased when combined with Cyclosporine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Cyclosporine.Approved, Withdrawn
AsunaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Cyclosporine can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Cyclosporine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Cyclosporine.Approved
AtracuriumCyclosporine may increase the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylateCyclosporine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Cyclosporine.Approved
AxitinibThe metabolism of Axitinib can be decreased when combined with Cyclosporine.Approved, Investigational
AzapropazoneAzapropazone may increase the nephrotoxic activities of Cyclosporine.Withdrawn
AzelastineAzelastine may increase the nephrotoxic activities of Cyclosporine.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilAzilsartan medoxomil may increase the hyperkalemic activities of Cyclosporine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Azimilide.Investigational
AzithromycinThe metabolism of Cyclosporine can be decreased when combined with Azithromycin.Approved
Bafilomycin A1The metabolism of Cyclosporine can be decreased when combined with Bafilomycin A1.Experimental
BalsalazideBalsalazide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Cyclosporine.Investigational
BarbexacloneThe metabolism of Cyclosporine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Cyclosporine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Barnidipine.Approved
BatimastatThe serum concentration of Cyclosporine can be increased when it is combined with Batimastat.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cyclosporine.Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Cyclosporine.Approved
BekanamycinBekanamycin may increase the nephrotoxic activities of Cyclosporine.Experimental
BenazeprilThe serum concentration of Cyclosporine can be increased when it is combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bencyclane.Experimental
BendazacBendazac may increase the nephrotoxic activities of Cyclosporine.Experimental
BenidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Benidipine.Approved, Investigational
BenorilateBenorilate may increase the nephrotoxic activities of Cyclosporine.Experimental
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Cyclosporine.Withdrawn
BenzamidineThe serum concentration of Cyclosporine can be increased when it is combined with Benzamidine.Experimental
Benzoic AcidThe metabolism of Cyclosporine can be decreased when combined with Benzoic Acid.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Cyclosporine.Approved, Illicit
BenzydamineBenzydamine may increase the nephrotoxic activities of Cyclosporine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Cyclosporine.Approved
BepridilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bepridil.Approved, Withdrawn
BevoniumBevonium may increase the nephrotoxic activities of Cyclosporine.Experimental
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Cyclosporine.Approved, Investigational
BezafibrateCyclosporine may increase the nephrotoxic activities of Bezafibrate.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Cyclosporine.Approved
BifonazoleThe metabolism of Cyclosporine can be decreased when combined with Bifonazole.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Cyclosporine.Approved
BivalirudinThe serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Cyclosporine.Approved, Withdrawn
BortezomibThe metabolism of Cyclosporine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Cyclosporine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cyclosporine.Approved
Brefeldin AThe metabolism of Cyclosporine can be decreased when combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Cyclosporine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Cyclosporine.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Cyclosporine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Cyclosporine.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Cyclosporine.Approved, Illicit
BromfenacBromfenac may increase the nephrotoxic activities of Cyclosporine.Approved
BromocriptineThe serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Cyclosporine.Approved
BucillamineBucillamine may increase the nephrotoxic activities of Cyclosporine.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Cyclosporine.Approved
BufexamacBufexamac may increase the nephrotoxic activities of Cyclosporine.Experimental
BumadizoneBumadizone may increase the nephrotoxic activities of Cyclosporine.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Cyclosporine.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Cyclosporine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Cyclosporine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Cyclosporine.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Cyclosporine.Approved, Investigational
ButenafineThe metabolism of Cyclosporine can be decreased when combined with Butenafine.Approved
ButoconazoleThe metabolism of Cyclosporine can be decreased when combined with Butoconazole.Approved
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Cyclosporine.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Cyclosporine.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Cyclosporine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Cyclosporine.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Cyclosporine.Approved, Nutraceutical
CamostatThe serum concentration of Cyclosporine can be increased when it is combined with Camostat.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Cyclosporine.Approved
CandesartanCandesartan may increase the hyperkalemic activities of Cyclosporine.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hyperkalemic activities of Cyclosporine.Approved
CandicidinThe metabolism of Cyclosporine can be decreased when combined with Candicidin.Withdrawn
CandoxatrilThe serum concentration of Cyclosporine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Cyclosporine can be increased when it is combined with Candoxatrilat.Experimental
Capric acidThe metabolism of Cyclosporine can be decreased when combined with Capric acid.Experimental
CaptoprilThe serum concentration of Cyclosporine can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the nephrotoxic activities of Cyclosporine.Experimental, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Cyclosporine.Approved
CarbomycinThe metabolism of Cyclosporine can be decreased when combined with Carbomycin.Vet Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Carboxyamidotriazole.Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Cyclosporine.Approved
CaroverineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Caroverine.Experimental
CarprofenCarprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.Approved
CastanospermineCastanospermine may increase the nephrotoxic activities of Cyclosporine.Experimental
CelecoxibCelecoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Cyclosporine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Cyclosporine.Approved, Vet Approved
CeritinibThe serum concentration of Cyclosporine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Cyclosporine.Withdrawn
CeruleninThe metabolism of Cyclosporine can be decreased when combined with Cerulenin.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Cyclosporine.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Cyclosporine.Approved
ChloramphenicolThe serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Cyclosporine.Approved, Illicit
ChloroquineChloroquine may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
ChloroxineThe metabolism of Cyclosporine can be decreased when combined with Chloroxine.Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Cyclosporine.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Cyclosporine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Cyclosporine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Cyclosporine.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Cyclosporine.Approved, Nutraceutical
CholesterolThe serum concentration of Cyclosporine can be increased when it is combined with Cholesterol.Experimental, Investigational
Cholic AcidCyclosporine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the nephrotoxic activities of Cyclosporine.Approved
ChymostatinThe serum concentration of Cyclosporine can be increased when it is combined with Chymostatin.Experimental
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Cyclosporine.Approved, Investigational
CiclopiroxThe metabolism of Cyclosporine can be decreased when combined with Ciclopirox.Approved, Investigational
CilastatinThe serum concentration of Cyclosporine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Cyclosporine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cilnidipine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Cyclosporine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Cyclosporine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Cinnarizine.Approved, Investigational
CiprofibrateCyclosporine may increase the nephrotoxic activities of Ciprofibrate.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cyclosporine.Approved, Investigational, Withdrawn
CisatracuriumCyclosporine may increase the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateCyclosporine may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
CitalopramThe metabolism of Citalopram can be decreased when combined with Cyclosporine.Approved
ClarithromycinThe metabolism of Cyclosporine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cyclosporine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Cyclosporine.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Cyclosporine.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Cyclosporine.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Cyclosporine.Approved, Investigational
ClofibrateCyclosporine may increase the nephrotoxic activities of Clofibrate.Approved, Investigational
ClofibrideCyclosporine may increase the nephrotoxic activities of Clofibride.Experimental
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Cyclosporine.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Cyclosporine.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Cyclosporine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Cyclosporine.Approved
ClonixinClonixin may increase the nephrotoxic activities of Cyclosporine.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Cyclosporine.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Cyclosporine.Approved, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.Approved
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Cyclosporine.Approved, Illicit
ClotrimazoleThe metabolism of Cyclosporine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Cyclosporine.Approved
CobicistatThe metabolism of Cyclosporine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cyclosporine.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Cyclosporine.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Cyclosporine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cyclosporine.Approved
ColesevelamThe serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Cyclosporine.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Cyclosporine.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Cyclosporine.Approved
CordycepinThe metabolism of Cyclosporine can be decreased when combined with Cordycepin.Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Cyclosporine.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.Approved
CrizotinibThe serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.Approved
CurcuminCurcumin may increase the nephrotoxic activities of Cyclosporine.Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.Approved
CyclophosphamideCyclophosphamide may increase the immunosuppressive activities of Cyclosporine.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Cyclosporine.Approved, Investigational
D-LimoneneD-Limonene may increase the nephrotoxic activities of Cyclosporine.Investigational
Dabigatran etexilateThe serum concentration of Cyclosporine can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Cyclosporine.Approved
DanazolDanazol may increase the hepatotoxic activities of Cyclosporine.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Cyclosporine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Cyclosporine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Cyclosporine.Approved, Investigational
DarexabanThe serum concentration of Cyclosporine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Cyclosporine.Approved, Investigational
DarodipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Darodipine.Experimental
DarunavirThe serum concentration of Cyclosporine can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Cyclosporine can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinDaunorubicin may increase the nephrotoxic activities of Cyclosporine.Approved
DecamethoniumCyclosporine may increase the neuromuscular blocking activities of Decamethonium.Approved
DeferasiroxThe serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Cyclosporine.Approved
DelanzomibThe serum concentration of Cyclosporine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Cyclosporine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Cyclosporine can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cyclosporine.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Cyclosporine.Approved, Investigational
DexamethasoneThe serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Cyclosporine.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Cyclosporine.Approved
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Cyclosporine.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Cyclosporine.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Cyclosporine.Approved, Illicit, Vet Approved
DibekacinDibekacin may increase the nephrotoxic activities of Cyclosporine.Experimental
DichloropheneThe metabolism of Cyclosporine can be decreased when combined with Dichlorophene.Vet Approved
DiclofenacDiclofenac may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Cyclosporine.Approved
DidanosineDidanosine can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Cyclosporine.Approved
DifenpiramideDifenpiramide may increase the nephrotoxic activities of Cyclosporine.Experimental
DiflunisalDiflunisal may increase the nephrotoxic activities of Cyclosporine.Approved
DigitoxinThe metabolism of Digitoxin can be decreased when combined with Cyclosporine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cyclosporine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Cyclosporine.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cyclosporine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cyclosporine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Cyclosporine.Experimental
DihydroergotamineThe metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinDihydrostreptomycin may increase the nephrotoxic activities of Cyclosporine.Investigational, Vet Approved
DihydrotestosteroneDihydrotestosterone may increase the hepatotoxic activities of Cyclosporine.Illicit
DiltiazemThe metabolism of Cyclosporine can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Cyclosporine.Approved
DisopyramideThe metabolism of Disopyramide can be decreased when combined with Cyclosporine.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Cyclosporine.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Cyclosporine.Approved, Investigational
DoconexentThe metabolism of Doconexent can be decreased when combined with Cyclosporine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Cyclosporine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Cyclosporine.Approved
Domoic AcidCyclosporine may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Cyclosporine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Cyclosporine.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Cyclosporine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dotarizine.Investigational
Doxacurium chlorideCyclosporine may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Cyclosporine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.Approved, Investigational
DoxorubicinDoxorubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
DoxycyclineThe metabolism of Cyclosporine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Cyclosporine.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.Approved
DroxicamDroxicam may increase the nephrotoxic activities of Cyclosporine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Cyclosporine.Approved, Investigational
DuvelisibDuvelisib may increase the nephrotoxic activities of Cyclosporine.Investigational
E-6201E-6201 may increase the nephrotoxic activities of Cyclosporine.Investigational
EcabetThe serum concentration of Cyclosporine can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe metabolism of Cyclosporine can be decreased when combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cyclosporine.Approved
EfavirenzThe serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Cyclosporine can be decreased when combined with Efinaconazole.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Efonidipine.Approved
ElafinThe serum concentration of Cyclosporine can be increased when it is combined with Elafin.Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Cyclosporine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cyclosporine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Cyclosporine.Approved
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Cyclosporine.Approved
EnalaprilThe serum concentration of Cyclosporine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Cyclosporine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Cyclosporine can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Cyclosporine.Approved
EnzalutamideThe serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Eperisone.Approved, Investigational
Epigallocatechin GallateThe serum concentration of Cyclosporine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Cyclosporine.Approved, Investigational
EpirizoleEpirizole may increase the nephrotoxic activities of Cyclosporine.Approved
EpirubicinEpirubicin may increase the nephrotoxic activities of Cyclosporine.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Cyclosporine.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Cyclosporine.Approved
EprosartanEprosartan may increase the hyperkalemic activities of Cyclosporine.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Cyclosporine.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Cyclosporine.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Cyclosporine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Cyclosporine.Approved, Investigational
ErythromycinThe metabolism of Cyclosporine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Cyclosporine.Approved, Investigational
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Cyclosporine.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Cyclosporine.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Cyclosporine.Approved, Investigational
EstramustineThe metabolism of Estramustine can be decreased when combined with Cyclosporine.Approved
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Cyclosporine.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Cyclosporine.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Cyclosporine.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Cyclosporine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.Approved
EtanerceptEtanercept may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Cyclosporine.Approved
EthenzamideEthenzamide may increase the nephrotoxic activities of Cyclosporine.Experimental
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Cyclosporine.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Cyclosporine.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Cyclosporine.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Cyclosporine.Approved
EtodolacEtodolac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
EtofibrateCyclosporine may increase the nephrotoxic activities of Etofibrate.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Cyclosporine.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Cyclosporine.Approved
EtoricoxibEtoricoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Cyclosporine.Approved
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cyclosporine.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Cyclosporine.Approved, Investigational
exisulindexisulind may increase the nephrotoxic activities of Cyclosporine.Investigational
EzetimibeThe serum concentration of Cyclosporine can be increased when it is combined with Ezetimibe.Approved
FaldaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Faldaprevir.Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Cyclosporine.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Cyclosporine.Approved
FelbinacFelbinac may increase the nephrotoxic activities of Cyclosporine.Experimental
FelodipineThe metabolism of Felodipine can be decreased when combined with Cyclosporine.Approved, Investigational
FenbufenFenbufen may increase the nephrotoxic activities of Cyclosporine.Approved
FendilineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Fendiline.Withdrawn
FenofibrateCyclosporine may increase the nephrotoxic activities of Fenofibrate.Approved
Fenofibric acidCyclosporine may increase the nephrotoxic activities of Fenofibric acid.Approved
FenoprofenFenoprofen may increase the nephrotoxic activities of Cyclosporine.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Cyclosporine.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may increase the nephrotoxic activities of Cyclosporine.Experimental
FenticonazoleThe metabolism of Cyclosporine can be decreased when combined with Fenticonazole.Experimental
FeprazoneFeprazone may increase the nephrotoxic activities of Cyclosporine.Experimental
Ferulic acidFerulic acid may increase the nephrotoxic activities of Cyclosporine.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine.Approved
FimasartanThe serum concentration of Fimasartan can be increased when it is combined with Cyclosporine.Approved, Investigational
FinasterideThe metabolism of Finasteride can be decreased when combined with Cyclosporine.Approved
FingolimodCyclosporine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Cyclosporine.Approved
FloctafenineFloctafenine may increase the nephrotoxic activities of Cyclosporine.Approved, Withdrawn
FluconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe metabolism of Cyclosporine can be decreased when combined with Flucytosine.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Flunarizine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Cyclosporine.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Cyclosporine.Approved, Illicit
FlunixinFlunixin may increase the nephrotoxic activities of Cyclosporine.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the nephrotoxic activities of Cyclosporine.Experimental
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Cyclosporine.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Cyclosporine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hepatotoxic activities of Cyclosporine.Approved, Illicit
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Cyclosporine.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Cyclosporine.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Cyclosporine.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be decreased when combined with Cyclosporine.Approved
FlutrimazoleThe metabolism of Cyclosporine can be decreased when combined with Flutrimazole.Experimental
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.Approved
FluvoxamineThe metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanForasartan may increase the hyperkalemic activities of Cyclosporine.Experimental
FormoterolThe metabolism of Formoterol can be decreased when combined with Cyclosporine.Approved, Investigational
FosamprenavirThe serum concentration of Cyclosporine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cyclosporine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the nephrotoxic activities of Cyclosporine.Approved
FosinoprilThe serum concentration of Cyclosporine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.Approved
FramycetinFramycetin may increase the nephrotoxic activities of Cyclosporine.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Cyclosporine.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Cyclosporine can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Cyclosporine.Investigational
GabapentinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gabapentin.Approved, Investigational
GabexateThe serum concentration of Cyclosporine can be increased when it is combined with Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Cyclosporine.Approved
GallamineCyclosporine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideCyclosporine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Gallopamil.Investigational
GavestinelThe metabolism of Gavestinel can be decreased when combined with Cyclosporine.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Cyclosporine.Approved, Investigational
GeldanamycinThe serum concentration of Cyclosporine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilCyclosporine may increase the nephrotoxic activities of Gemfibrozil.Approved
GeneticinGeneticin may increase the nephrotoxic activities of Cyclosporine.Experimental
GentamicinGentamicin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the nephrotoxic activities of Cyclosporine.Experimental
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cyclosporine.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Cyclosporine.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Cyclosporine.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Cyclosporine.Approved
GLPG-0492GLPG-0492 may increase the hepatotoxic activities of Cyclosporine.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.Approved
GlyphosateThe metabolism of Cyclosporine can be decreased when combined with Glyphosate.Experimental
GM6001The serum concentration of Cyclosporine can be increased when it is combined with GM6001.Experimental
GPX-150GPX-150 may increase the nephrotoxic activities of Cyclosporine.Investigational
GranisetronThe metabolism of Granisetron can be decreased when combined with Cyclosporine.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Cyclosporine.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Cyclosporine.Investigational, Withdrawn
GriseofulvinThe serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.Approved, Vet Approved
GuacetisalGuacetisal may increase the nephrotoxic activities of Cyclosporine.Experimental
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Cyclosporine.Approved, Investigational
HachimycinThe metabolism of Cyclosporine can be decreased when combined with Hachimycin.Experimental
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Cyclosporine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Cyclosporine.Approved
HaloproginThe metabolism of Cyclosporine can be decreased when combined with Haloprogin.Approved, Withdrawn
HalothaneThe metabolism of Halothane can be decreased when combined with Cyclosporine.Approved, Vet Approved
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclosporine.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.Approved, Withdrawn
HexetidineThe metabolism of Cyclosporine can be decreased when combined with Hexetidine.Approved, Investigational
HexobarbitalThe metabolism of Cyclosporine can be increased when combined with Hexobarbital.Approved
HigenamineHigenamine may increase the nephrotoxic activities of Cyclosporine.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Cyclosporine.Approved, Investigational
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Cyclosporine.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Cyclosporine.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Cyclosporine.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Cyclosporine.Approved
Hygromycin BHygromycin B may increase the nephrotoxic activities of Cyclosporine.Vet Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Cyclosporine.Approved
IbuprofenIbuprofen may increase the nephrotoxic activities of Cyclosporine.Approved
IbuproxamIbuproxam may increase the nephrotoxic activities of Cyclosporine.Withdrawn
IcatibantIcatibant may increase the nephrotoxic activities of Cyclosporine.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Cyclosporine.Approved, Investigational
IdarubicinIdarubicin may increase the nephrotoxic activities of Cyclosporine.Approved
IdelalisibThe serum concentration of Cyclosporine can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Cyclosporine can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Cyclosporine resulting in a loss in efficacy.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Cyclosporine.Approved
ImatinibThe serum concentration of Cyclosporine can be increased when it is combined with Imatinib.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Cyclosporine.Approved, Investigational
ImidaprilThe serum concentration of Cyclosporine can be increased when it is combined with Imidapril.Investigational
Imidazole salicylateImidazole salicylate may increase the nephrotoxic activities of Cyclosporine.Experimental
ImipenemCyclosporine may increase the neurotoxic activities of Imipenem.Approved
ImipramineThe metabolism of Imipramine can be decreased when combined with Cyclosporine.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Cyclosporine.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Cyclosporine.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Cyclosporine.Approved
IndinavirThe serum concentration of Cyclosporine can be increased when it is combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Cyclosporine.Investigational
IndobufenIndobufen may increase the nephrotoxic activities of Cyclosporine.Investigational
IndomethacinIndomethacin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
IndoprofenIndoprofen may increase the nephrotoxic activities of Cyclosporine.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Cyclosporine.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cyclosporine.Investigational
INNO-206INNO-206 may increase the nephrotoxic activities of Cyclosporine.Investigational
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Cyclosporine.Approved
IrbesartanIrbesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational
IrinotecanThe metabolism of Irinotecan can be decreased when combined with Cyclosporine.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Cyclosporine.Approved, Investigational
IsepamicinIsepamicin may increase the nephrotoxic activities of Cyclosporine.Experimental
IsoconazoleThe metabolism of Cyclosporine can be decreased when combined with Isoconazole.Approved
IsoflurophateThe serum concentration of Cyclosporine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Cyclosporine.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Cyclosporine.Approved
IsoxicamIsoxicam may increase the nephrotoxic activities of Cyclosporine.Withdrawn
IsradipineThe metabolism of Isradipine can be decreased when combined with Cyclosporine.Approved
ItraconazoleThe metabolism of Cyclosporine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Cyclosporine.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Cyclosporine.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Cyclosporine.Approved, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Cyclosporine.Approved, Investigational
IxazomibThe serum concentration of Cyclosporine can be increased when it is combined with Ixazomib.Approved
JosamycinThe metabolism of Cyclosporine can be decreased when combined with Josamycin.Approved, Investigational
KanamycinKanamycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
KebuzoneKebuzone may increase the nephrotoxic activities of Cyclosporine.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Cyclosporine.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Cyclosporine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Cyclosporine.Approved, Investigational
KetoconazoleThe metabolism of Cyclosporine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
KetorolacKetorolac may increase the nephrotoxic activities of Cyclosporine.Approved
KitasamycinThe metabolism of Cyclosporine can be decreased when combined with Kitasamycin.Experimental
LacidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lamotrigine.Approved, Investigational
LanreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Cyclosporine.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Cyclosporine.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Cyclosporine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cyclosporine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Leflunomide.Approved, Investigational
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Cyclosporine.Approved
LepirudinThe serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe serum concentration of Cyclosporine can be increased when it is combined with Lercanidipine.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Cyclosporine.Approved
LetaxabanThe serum concentration of Cyclosporine can be increased when it is combined with Letaxaban.Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Cyclosporine.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Cyclosporine.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Cyclosporine.Approved
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Cyclosporine.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Cyclosporine.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Cyclosporine.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Cyclosporine.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Cyclosporine.Approved, Vet Approved
LidoflazineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Lidoflazine.Experimental
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Cyclosporine.Approved
LisinoprilThe serum concentration of Cyclosporine can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the nephrotoxic activities of Cyclosporine.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Cyclosporine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Cyclosporine.Approved
LonazolacLonazolac may increase the nephrotoxic activities of Cyclosporine.Experimental
LoperamideThe metabolism of Loperamide can be decreased when combined with Cyclosporine.Approved
LopinavirThe serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Cyclosporine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Cyclosporine.Approved
LornoxicamLornoxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Cyclosporine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.Approved, Investigational
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
LuliconazoleThe serum concentration of Cyclosporine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Cyclosporine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Cyclosporine.Approved
LumiracoxibLumiracoxib may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Cyclosporine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Cyclosporine.Illicit, Investigational, Withdrawn
MacitentanThe metabolism of Macitentan can be decreased when combined with Cyclosporine.Approved
Magnesium salicylateMagnesium salicylate may increase the nephrotoxic activities of Cyclosporine.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Manidipine.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Cyclosporine.Approved, Investigational
MasoprocolMasoprocol may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Cyclosporine.Approved, Vet Approved
Meclofenamic acidMeclofenamic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Cyclosporine.Approved, Investigational
Mefenamic acidMefenamic acid may increase the nephrotoxic activities of Cyclosporine.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Cyclosporine.Approved
MelagatranThe serum concentration of Cyclosporine can be increased when it is combined with Melagatran.Experimental
MelatoninThe metabolism of Melatonin can be decreased when combined with Cyclosporine.Approved, Nutraceutical, Vet Approved
MeloxicamMeloxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
MelphalanMelphalan may increase the nephrotoxic activities of Cyclosporine.Approved
MepartricinThe metabolism of Cyclosporine can be decreased when combined with Mepartricin.Experimental
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Cyclosporine.Investigational, Withdrawn
MesalazineMesalazine may increase the nephrotoxic activities of Cyclosporine.Approved
MesteroloneMesterolone may increase the hepatotoxic activities of Cyclosporine.Experimental
MestranolThe metabolism of Mestranol can be decreased when combined with Cyclosporine.Approved
MetamizoleMetamizole may increase the nephrotoxic activities of Cyclosporine.Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Cyclosporine.Experimental
MethadoneThe metabolism of Methadone can be decreased when combined with Cyclosporine.Approved
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Cyclosporine.Illicit, Withdrawn
MethohexitalThe metabolism of Cyclosporine can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Cyclosporine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Cyclosporine.Approved
MethylphenobarbitalThe metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hepatotoxic activities of Cyclosporine.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Cyclosporine.Approved
MetoclopramideMetoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MetocurineCyclosporine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideCyclosporine may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cyclosporine.Approved, Investigational
MetreleptinThe serum concentration of Cyclosporine can be decreased when it is combined with Metreleptin.Approved
MetrizamideMetrizamide may increase the nephrotoxic activities of Cyclosporine.Approved
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Cyclosporine.Approved
MevastatinThe metabolism of Cyclosporine can be decreased when combined with Mevastatin.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Cyclosporine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Cyclosporine.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Mibefradil.Investigational, Withdrawn
MicafunginThe metabolism of Cyclosporine can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Cyclosporine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinMicronomicin may increase the nephrotoxic activities of Cyclosporine.Experimental
MidazolamThe metabolism of Midazolam can be decreased when combined with Cyclosporine.Approved, Illicit
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Cyclosporine.Approved
MifepristoneThe serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe metabolism of Cyclosporine can be decreased when combined with Miltefosine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Cyclosporine.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Cyclosporine.Approved
MitotaneThe serum concentration of Cyclosporine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.Approved, Investigational
MivacuriumCyclosporine may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineMizoribine may increase the nephrotoxic activities of Cyclosporine.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Cyclosporine.Approved
ModafinilThe serum concentration of Cyclosporine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Cyclosporine can be increased when it is combined with Moexipril.Approved
MofebutazoneMofebutazone may increase the nephrotoxic activities of Cyclosporine.Experimental
MonensinThe metabolism of Cyclosporine can be decreased when combined with Monensin.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Cyclosporine.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Cyclosporine.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.Approved
MyxothiazolThe metabolism of Cyclosporine can be decreased when combined with Myxothiazol.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Cyclosporine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneNabumetone may increase the nephrotoxic activities of Cyclosporine.Approved
NafamostatThe serum concentration of Cyclosporine can be increased when it is combined with Nafamostat.Approved, Investigational
NafcillinThe metabolism of Cyclosporine can be increased when combined with Nafcillin.Approved
NaftifineThe metabolism of Cyclosporine can be decreased when combined with Naftifine.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cyclosporine.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Cyclosporine.Approved, Vet Approved
NandroloneNandrolone may increase the hepatotoxic activities of Cyclosporine.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hepatotoxic activities of Cyclosporine.Approved, Illicit
NaproxenNaproxen may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Natalizumab.Approved, Investigational
NatamycinThe metabolism of Cyclosporine can be decreased when combined with Natamycin.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Cyclosporine.Approved, Investigational
NeamineNeamine may increase the nephrotoxic activities of Cyclosporine.Experimental
NefazodoneThe metabolism of Cyclosporine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Cyclosporine can be increased when it is combined with Nelfinavir.Approved
NeomycinNeomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
NeosaxitoxinCyclosporine may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacNepafenac may increase the nephrotoxic activities of Cyclosporine.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Cyclosporine.Approved, Investigational
NetilmicinNetilmicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
NetupitantThe serum concentration of Cyclosporine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cyclosporine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Cyclosporine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Cyclosporine.Approved, Investigational
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Cyclosporine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Cyclosporine.Approved
NifenazoneNifenazone may increase the nephrotoxic activities of Cyclosporine.Experimental
Niflumic AcidNiflumic Acid may increase the nephrotoxic activities of Cyclosporine.Approved
NifuratelThe metabolism of Cyclosporine can be decreased when combined with Nifuratel.Experimental
NiguldipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Niguldipine.Experimental
Nikkomycin ZThe metabolism of Cyclosporine can be decreased when combined with Nikkomycin Z.Investigational
NilotinibThe metabolism of Nilotinib can be decreased when combined with Cyclosporine.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nilvadipine.Approved, Investigational
NimesulideNimesulide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Cyclosporine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Cyclosporine.Approved
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Cyclosporine.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Cyclosporine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nitrendipine.Approved, Investigational
NitroaspirinThe serum concentration of Cyclosporine can be increased when it is combined with Nitroaspirin.Investigational
NitroxolineThe metabolism of Cyclosporine can be decreased when combined with Nitroxoline.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Cyclosporine.Approved
NorfloxacinThe metabolism of Cyclosporine can be decreased when combined with Norfloxacin.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Cyclosporine.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Cyclosporine.Approved
NystatinThe metabolism of Cyclosporine can be decreased when combined with Nystatin.Approved, Vet Approved
OctreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Cyclosporine.Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Cyclosporine.Approved
OleandomycinThe metabolism of Cyclosporine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Cyclosporine.Approved
OlopatadineOlopatadine may increase the nephrotoxic activities of Cyclosporine.Approved
OlsalazineOlsalazine may increase the nephrotoxic activities of Cyclosporine.Approved
OmapatrilatThe serum concentration of Cyclosporine can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Cyclosporine can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe metabolism of Cyclosporine can be decreased when combined with Omoconazole.Experimental
OndansetronThe metabolism of Ondansetron can be decreased when combined with Cyclosporine.Approved
OrgoteinOrgotein may increase the nephrotoxic activities of Cyclosporine.Vet Approved
OrlistatThe serum concentration of Cyclosporine can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Cyclosporine.Approved
OsimertinibThe serum concentration of Cyclosporine can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Cyclosporine.Approved
OtamixabanThe serum concentration of Cyclosporine can be increased when it is combined with Otamixaban.Investigational
OtiloniumThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Otilonium.Experimental, Investigational
OxandroloneOxandrolone may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational
OxaprozinOxaprozin may increase the nephrotoxic activities of Cyclosporine.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Cyclosporine.Approved
OxiconazoleThe metabolism of Cyclosporine can be decreased when combined with Oxiconazole.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Cyclosporine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Oxycodone.Approved, Illicit, Investigational
OxymetholoneOxymetholone may increase the hepatotoxic activities of Cyclosporine.Approved, Illicit
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Cyclosporine.Approved, Withdrawn
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Cyclosporine.Approved, Vet Approved
pafuramidineThe metabolism of Cyclosporine can be decreased when combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Cyclosporine can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Cyclosporine.Approved, Investigational
PancuroniumCyclosporine may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe metabolism of Panobinostat can be decreased when combined with Cyclosporine.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Cyclosporine.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Cyclosporine.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Cyclosporine.Approved
ParecoxibParecoxib may increase the nephrotoxic activities of Cyclosporine.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Cyclosporine.Approved, Investigational
ParitaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Paritaprevir.Approved
ParomomycinParomomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
ParthenolideParthenolide may increase the nephrotoxic activities of Cyclosporine.Investigational
PasireotideThe serum concentration of Cyclosporine can be decreased when it is combined with Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.Approved
PentamidineThe metabolism of Cyclosporine can be decreased when combined with Pentamidine.Approved
PentobarbitalThe metabolism of Cyclosporine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Cyclosporine.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Perhexiline.Approved, Investigational
PerindoprilThe serum concentration of Cyclosporine can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Cyclosporine.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Cyclosporine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Cyclosporine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Cyclosporine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Cyclosporine.Withdrawn
PhenobarbitalThe metabolism of Cyclosporine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Cyclosporine.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
PhenytoinThe metabolism of Cyclosporine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Cyclosporine can be increased when it is combined with Phosphoramidon.Experimental
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Cyclosporine.Approved
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
PimozideCyclosporine may increase the arrhythmogenic activities of Pimozide.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Cyclosporine.Withdrawn
PinaveriumThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pinaverium.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Cyclosporine.Approved, Investigational
PipecuroniumCyclosporine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Cyclosporine.Approved, Investigational
PirarubicinPirarubicin may increase the nephrotoxic activities of Cyclosporine.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.Experimental
PirfenidonePirfenidone may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
PiroxicamPiroxicam may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
PirprofenPirprofen may increase the nephrotoxic activities of Cyclosporine.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.Approved
PlazomicinPlazomicin may increase the nephrotoxic activities of Cyclosporine.Investigational
PlicamycinPlicamycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Withdrawn
PodofiloxThe metabolism of Podofilox can be decreased when combined with Cyclosporine.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Cyclosporine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Cyclosporine.Approved
PosaconazoleThe metabolism of Cyclosporine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may increase the nephrotoxic activities of Cyclosporine.Experimental, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Cyclosporine.Approved, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Cyclosporine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Cyclosporine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Cyclosporine.Approved, Vet Approved
PrednisoloneThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe serum concentration of the active metabolites of Prednisone can be increased when Prednisone is used in combination with Cyclosporine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Prenylamine.Withdrawn
PrimaquineThe metabolism of Primaquine can be decreased when combined with Cyclosporine.Approved
PrimidoneThe metabolism of Cyclosporine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Cyclosporine can be increased when it is combined with Prinomastat.Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Cyclosporine.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cyclosporine.Approved, Vet Approved
ProglumetacinProglumetacin may increase the nephrotoxic activities of Cyclosporine.Experimental
ProguanilThe metabolism of Proguanil can be decreased when combined with Cyclosporine.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Cyclosporine.Approved, Vet Approved
PropacetamolPropacetamol may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Cyclosporine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe metabolism of Propoxyphene napsylate can be decreased when combined with Cyclosporine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Cyclosporine.Approved, Investigational
PropyphenazonePropyphenazone may increase the nephrotoxic activities of Cyclosporine.Experimental
ProquazoneProquazone may increase the nephrotoxic activities of Cyclosporine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.Approved
PTC299PTC299 may increase the nephrotoxic activities of Cyclosporine.Investigational
PuromycinPuromycin may increase the nephrotoxic activities of Cyclosporine.Experimental
PyrantelCyclosporine may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
PyrazinamideThe serum concentration of Cyclosporine can be increased when it is combined with Pyrazinamide.Approved
PyrrolnitrinThe metabolism of Cyclosporine can be decreased when combined with Pyrrolnitrin.Experimental
QuazepamThe metabolism of Quazepam can be decreased when combined with Cyclosporine.Approved, Illicit
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Cyclosporine.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Cyclosporine.Approved, Investigational
QuinaprilThe serum concentration of Cyclosporine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Quinidine can be decreased when combined with Cyclosporine.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Cyclosporine.Approved
QuinupristinThe serum concentration of Cyclosporine can be increased when it is combined with Quinupristin.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Cyclosporine.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cyclosporine.Approved
RacecadotrilThe serum concentration of Cyclosporine can be increased when it is combined with Racecadotril.Investigational
RadicicolThe metabolism of Cyclosporine can be decreased when combined with Radicicol.Experimental
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Cyclosporine.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Cyclosporine.Approved, Investigational
RamiprilThe serum concentration of Cyclosporine can be increased when it is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cyclosporine.Approved, Investigational
RapacuroniumCyclosporine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Cyclosporine.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Cyclosporine.Approved
RemikirenThe serum concentration of Cyclosporine can be increased when it is combined with Remikiren.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.Approved, Investigational
ResveratrolResveratrol may increase the nephrotoxic activities of Cyclosporine.Approved, Experimental, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Cyclosporine.Approved
RibostamycinRibostamycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
RifabutinThe metabolism of Cyclosporine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cyclosporine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cyclosporine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.Approved, Investigational
RilpivirineThe metabolism of Rilpivirine can be decreased when combined with Cyclosporine.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Cyclosporine.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cyclosporine.Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Cyclosporine.Approved
RisedronateThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Risedronate.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Cyclosporine.Approved, Investigational
RitonavirThe serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Cyclosporine can be increased when it is combined with Rivaroxaban.Approved
RocuroniumCyclosporine may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibRofecoxib may increase the nephrotoxic activities of Cyclosporine.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Cyclosporine.Approved
RolapitantThe metabolism of Rolapitant can be decreased when combined with Cyclosporine.Approved
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Cyclosporine.Approved, Investigational
RonifibrateCyclosporine may increase the nephrotoxic activities of Ronifibrate.Experimental
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Cyclosporine.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Cyclosporine.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Cyclosporine.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Cyclosporine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Cyclosporine.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cyclosporine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Cyclosporine.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Cyclosporine.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Cyclosporine.Approved
S-3304The serum concentration of Cyclosporine can be increased when it is combined with S-3304.Investigational
SabarubicinSabarubicin may increase the nephrotoxic activities of Cyclosporine.Investigational
SacubitrilSacubitril may increase the hyperkalemic activities of Cyclosporine.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Cyclosporine.Approved
SalicylamideSalicylamide may increase the nephrotoxic activities of Cyclosporine.Approved
Salicylhydroxamic AcidThe metabolism of Cyclosporine can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Cyclosporine can be decreased when combined with Salicylic acid.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Cyclosporine.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Cyclosporine.Approved
SalsalateSalsalate may increase the nephrotoxic activities of Cyclosporine.Approved
SaprisartanSaprisartan may increase the hyperkalemic activities of Cyclosporine.Experimental
SaquinavirThe serum concentration of Cyclosporine can be increased when it is combined with Saquinavir.Approved, Investigational
SaralasinSaralasin may increase the hyperkalemic activities of Cyclosporine.Investigational
SaxagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Saxagliptin.Approved
SecobarbitalThe metabolism of Cyclosporine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Cyclosporine.Approved
SemapimodSemapimod may increase the nephrotoxic activities of Cyclosporine.Investigational
SeratrodastSeratrodast may increase the nephrotoxic activities of Cyclosporine.Approved
SerrapeptaseSerrapeptase may increase the nephrotoxic activities of Cyclosporine.Investigational
SertaconazoleThe metabolism of Cyclosporine can be decreased when combined with Sertaconazole.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Cyclosporine.Approved
SevelamerThe serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Cyclosporine.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Cyclosporine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Cyclosporine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cyclosporine.Approved
SiltuximabThe serum concentration of Cyclosporine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cyclosporine can be increased when it is combined with Simeprevir.Approved
SimfibrateCyclosporine may increase the nephrotoxic activities of Simfibrate.Experimental
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.Approved
SinefunginThe metabolism of Cyclosporine can be decreased when combined with Sinefungin.Experimental
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cyclosporine.Approved, Investigational
SisomicinSisomicin may increase the nephrotoxic activities of Cyclosporine.Investigational
SitagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanThe serum concentration of Sitaxentan can be increased when it is combined with Cyclosporine.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Cyclosporine can be increased when it is combined with Sivelestat.Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Cyclosporine.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Cyclosporine.Approved
SolithromycinThe metabolism of Cyclosporine can be decreased when combined with Solithromycin.Investigational
SomatostatinThe serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin.Approved, Investigational
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Cyclosporine.Approved, Investigational
SorafenibThe metabolism of Sorafenib can be decreased when combined with Cyclosporine.Approved, Investigational
SP1049CSP1049C may increase the nephrotoxic activities of Cyclosporine.Investigational
SpectinomycinSpectinomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Cyclosporine.Approved
SpiraprilThe serum concentration of Cyclosporine can be increased when it is combined with Spirapril.Approved
SpironolactoneSpironolactone may increase the hyperkalemic activities of Cyclosporine.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cyclosporine.Investigational
SRT501SRT501 may increase the nephrotoxic activities of Cyclosporine.Investigational
St. John's WortThe serum concentration of Cyclosporine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololStanozolol may increase the hepatotoxic activities of Cyclosporine.Approved, Vet Approved
StiripentolThe serum concentration of Cyclosporine can be increased when it is combined with Stiripentol.Approved
StreptomycinStreptomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
StreptozocinStreptozocin may increase the nephrotoxic activities of Cyclosporine.Approved
SuccinylcholineCyclosporine may increase the neuromuscular blocking activities of Succinylcholine.Approved
SucralfateSucralfate can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Cyclosporine.Approved, Investigational
SulconazoleThe metabolism of Cyclosporine can be decreased when combined with Sulconazole.Approved
SulfadiazineSulfadiazine may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the nephrotoxic activities of Cyclosporine.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Cyclosporine.Approved
SulfasalazineSulfasalazine may increase the nephrotoxic activities of Cyclosporine.Approved
SulfinpyrazoneThe serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the nephrotoxic activities of Cyclosporine.Approved, Vet Approved
SulindacSulindac may increase the nephrotoxic activities of Cyclosporine.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Cyclosporine.Approved, Investigational
SuprofenSuprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Cyclosporine.Approved
SuxibuzoneSuxibuzone may increase the nephrotoxic activities of Cyclosporine.Experimental
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Cyclosporine.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Cyclosporine.Approved
TacrolimusTacrolimus may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Cyclosporine.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Cyclosporine.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Cyclosporine.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Cyclosporine.Approved
TarenflurbilTarenflurbil may increase the nephrotoxic activities of Cyclosporine.Investigational
TasosartanTasosartan may increase the hyperkalemic activities of Cyclosporine.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Cyclosporine.Experimental
TavaboroleThe metabolism of Cyclosporine can be decreased when combined with Tavaborole.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Cyclosporine.Investigational
TelaprevirThe serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Cyclosporine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Cyclosporine.Approved
TemocaprilThe serum concentration of Cyclosporine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Cyclosporine.Approved
TenidapTenidap may increase the nephrotoxic activities of Cyclosporine.Experimental
TeniposideThe metabolism of Teniposide can be decreased when combined with Cyclosporine.Approved
TenoxicamTenoxicam may increase the nephrotoxic activities of Cyclosporine.Approved
TepoxalinTepoxalin may increase the nephrotoxic activities of Cyclosporine.Vet Approved
TerbinafineThe metabolism of Cyclosporine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Cyclosporine can be decreased when combined with Terconazole.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Cyclosporine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Cyclosporine.Experimental
TeriflunomideTeriflunomide may increase the nephrotoxic activities of Cyclosporine.Approved
TerodilineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Terodiline.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Cyclosporine.Investigational
TestosteroneTestosterone may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational
Testosterone PropionateTestosterone Propionate may increase the hepatotoxic activities of Cyclosporine.Approved, Vet Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Cyclosporine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tetrahydropalmatine.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Cyclosporine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Cyclosporine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Cyclosporine.Approved
ThiamylalThe metabolism of Cyclosporine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Cyclosporine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cyclosporine.Approved, Withdrawn
ThiorphanThe serum concentration of Cyclosporine can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Cyclosporine.Approved
ThymolThe metabolism of Cyclosporine can be decreased when combined with Thymol.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Cyclosporine.Approved
Tiaprofenic acidTiaprofenic acid may increase the nephrotoxic activities of Cyclosporine.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.Approved
TiclopidineThe metabolism of Cyclosporine can be decreased when combined with Ticlopidine.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Cyclosporine.Approved, Investigational
TinoridineTinoridine may increase the nephrotoxic activities of Cyclosporine.Investigational
TioconazoleThe metabolism of Cyclosporine can be decreased when combined with Tioconazole.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Cyclosporine.Approved
TipranavirThe serum concentration of Cyclosporine can be increased when it is combined with Tipranavir.Approved, Investigational
TobramycinTobramycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
TocilizumabThe serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibCyclosporine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Cyclosporine.Approved
TolciclateThe metabolism of Cyclosporine can be decreased when combined with Tolciclate.Experimental
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Cyclosporine.Approved
TolmetinTolmetin may increase the nephrotoxic activities of Cyclosporine.Approved
TolnaftateThe metabolism of Cyclosporine can be decreased when combined with Tolnaftate.Approved, Vet Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Cyclosporine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cyclosporine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cyclosporine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.Approved
ToremifeneThe metabolism of Toremifene can be decreased when combined with Cyclosporine.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Cyclosporine.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Cyclosporine.Approved, Investigational
TrandolaprilThe serum concentration of Cyclosporine can be increased when it is combined with Trandolapril.Approved
TranilastTranilast may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Cyclosporine.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Cyclosporine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Cyclosporine.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Cyclosporine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Cyclosporine.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Cyclosporine.Approved, Vet Approved
TriamtereneTriamterene may increase the hyperkalemic activities of Cyclosporine.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Cyclosporine.Approved
TribenosideTribenoside may increase the nephrotoxic activities of Cyclosporine.Experimental
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Cyclosporine.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Cyclosporine.Approved, Vet Approved
TrimetrexateThe metabolism of Cyclosporine can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Cyclosporine.Approved
TriptolideTriptolide may increase the nephrotoxic activities of Cyclosporine.Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Cyclosporine.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Cyclosporine.Approved
TubocurarineCyclosporine may increase the neuromuscular blocking activities of Tubocurarine.Approved
TylosinThe metabolism of Cyclosporine can be decreased when combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Cyclosporine can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Cyclosporine.Approved, Experimental
UdenafilThe metabolism of Udenafil can be decreased when combined with Cyclosporine.Approved, Investigational
UlinastatinThe serum concentration of Cyclosporine can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cyclosporine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Cyclosporine.Approved, Investigational
ValdecoxibValdecoxib may increase the nephrotoxic activities of Cyclosporine.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Cyclosporine.Approved, Investigational
ValrubicinValrubicin may increase the nephrotoxic activities of Cyclosporine.Approved
ValsartanValsartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Cyclosporine.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Cyclosporine.Investigational
VapreotideThe serum concentration of Cyclosporine can be decreased when it is combined with Vapreotide.Approved, Investigational
VardenafilThe metabolism of Vardenafil can be decreased when combined with Cyclosporine.Approved
VecuroniumCyclosporine may increase the neuromuscular blocking activities of Vecuronium.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Cyclosporine.Approved
VemurafenibThe metabolism of Vemurafenib can be decreased when combined with Cyclosporine.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Cyclosporine.Approved
VenlafaxineThe metabolism of Cyclosporine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Cyclosporine can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Cyclosporine.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Cyclosporine.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Cyclosporine.Approved
VildagliptinThe serum concentration of Cyclosporine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Cyclosporine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Cyclosporine.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Cyclosporine.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Cyclosporine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Cyclosporine.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Vinpocetine.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Cyclosporine.Approved
Vitamin CThe serum concentration of Cyclosporine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
Vitamin EThe serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Cyclosporine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Cyclosporine.Approved
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Cyclosporine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Cyclosporine.Approved
XimelagatranThe serum concentration of Cyclosporine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Xylometazoline.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cyclosporine.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Cyclosporine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Cyclosporine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Cyclosporine.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Cyclosporine.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Cyclosporine.Approved, Illicit, Investigational
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Ziconotide.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Cyclosporine.Approved
ZileutonZileuton may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Cyclosporine can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Cyclosporine can be increased when it is combined with Zofenopril.Experimental
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Cyclosporine.Approved
ZomepiracZomepirac may increase the nephrotoxic activities of Cyclosporine.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Cyclosporine.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Cyclosporine.Approved
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the nephrotoxic activities of Cyclosporine.Investigational
ZorubicinZorubicin may increase the nephrotoxic activities of Cyclosporine.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Cyclosporine.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine.Approved, Investigational
Food Interactions
  • Avoid salt substitutes containing potassium.
  • Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.
  • Red wine may reduce cyclosporine levels due to increased metabolism, therefore it appears prudent to avoid red wine (white wine does not appear to affect cyclosporine metabolism).
  • When taken with a meal, AUC and Cmax of cyclosporine modified decreased.

References

Synthesis Reference

Hans Dietl, "Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production." U.S. Patent US5527537, issued October, 1990.

US5527537
General References
  1. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30;330(26):1841-5. [PubMed:8196726]
  2. Husi H, Schorgendorfer K, Stempfer G, Taylor P, Walkinshaw MD: Prediction of substrate-specific pockets in cyclosporin synthetase. FEBS Lett. 1997 Sep 15;414(3):532-6. [PubMed:9323029]
  3. Link [Link]
External Links
KEGG Drug
D00184
KEGG Compound
C05086
PubChem Compound
5284373
PubChem Substance
46508198
ChemSpider
4447449
BindingDB
50022815
ChEBI
4031
ChEMBL
CHEMBL160
Therapeutic Targets Database
DNC001177
PharmGKB
PA449167
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cyclosporine
ATC Codes
S01XA18 — CiclosporinL04AD01 — Ciclosporin
AHFS Codes
  • 52:08.92 — Anti-inflammatory Agents, Miscellaneous
  • 92:44.00 — Immunosuppressive Agents
FDA label
Download (176 KB)
MSDS
Download (83.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Neuroepithelial Tumor / Tumors, Solid1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Secondary Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdenosine Deaminase Deficiency / Autosomal Recessive Disorder / Immune System Disorder / Purine-Nucleoside Phosphorylase Deficiency / Severe Combined Immunodeficiency / Severe Combined Immunodeficiency With Absence of T and B Cells / X-linked Severe Combined Immunodeficiency1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentRecurrent Colorectal Carcinoma / Solid Neoplasms / Stage IIIA Colorectal Cancer / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIB Colorectal Cancer / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIC Colorectal Cancer / Stage IIIC Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v71
1CompletedNot AvailableDry Eye Syndromes1
1CompletedNot AvailableHealthy Volunteers4
1CompletedBasic ScienceChronic Hepatitis C Infection1
1CompletedBasic ScienceDrug Interactions / Healthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers4
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics / Venous Thromboembolism1
1CompletedOtherPurpura, Thrombocytopenic, Idiopathic1
1CompletedPreventionHealthy Volunteers1
1CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
1CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / Congenital Hypoplastic Anemia / Previously Treated Myelodysplastic Syndromes1
1CompletedTreatmentAnemias / Leukemia, T-Cell / Lymphocytosis / Neutropenias / Thrombocytopenias1
1CompletedTreatmentCholesterol1
1CompletedTreatmentChronic Graft Versus Host Disease1
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Immunosuppression / Transplantation, Organ1
1CompletedTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts / Secondary Acute Myeloid Leukemia1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentCongenital Hypoplastic Anemia1
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas / Neutropenias / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentEnd Stage Renal Disease (ESRD) / Multiple Myeloma (MM)1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHepatitis C Virus (HCV)1
1CompletedTreatmentHereditary Angioedema1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia Lymphoblastic, Acute / Neoplasm Recurrent1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute1
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
1CompletedTreatmentNeuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentOsteogenesis Imperfecta1
1CompletedTreatmentRenal Replacement Therapies1
1RecruitingTreatmentCD30-Positive Neoplastic Cells Present / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Sickle Cell Disorders1
1SuspendedTreatmentPlasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1TerminatedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Relapsing Chronic Myelogenous Leukemia1
1TerminatedTreatmentAplastic Anaemia (AA)1
1TerminatedTreatmentCardiac Surgical Procedures1
1TerminatedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Secondary Myelofibrosis1
1TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1Unknown StatusSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1Unknown StatusTreatmentCancer, Breast2
1Unknown StatusTreatmentMalignant Lymphomas2
1Unknown StatusTreatmentMelanoma (Skin)1
1Unknown StatusTreatmentProstate Cancer1
1Unknown StatusTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Childhood Renal Cell Carcinoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Clear Cell Renal Cell Carcinoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Renal Cell Cancer / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Renal Cell Cancer / T-Cell Large Granular Lymphocyte Leukemia / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Malignant mast cell neoplasm / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myeloid/NK-cell Acute Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Renal Cell Cancer / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Multiple Myeloma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndrome / Childhood Renal Cell Carcinoma / Chronic Myelomonocytic Leukemia / Clear Cell Renal Cell Carcinoma / De Novo Myelodysplastic Syndrome / Metastatic Renal Cell Cancer / Previously Treated Myelodysplastic Syndromes / Progression of Multiple Myeloma or Plasma Cell Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Renal Medullary Carcinoma / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2Active Not RecruitingTreatmentComplete Atypical DiGeorge Anomaly / Complete Atypical DiGeorge Syndrome / Complete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly1
1, 2Active Not RecruitingTreatmentLeukaemia, Acute / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Disease1
1, 2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentRecurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2CompletedPreventionTransplant, Kidney1
1, 2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
1, 2CompletedTreatmentAplastic Anaemia (AA) / Neutropenias / Pancytopenia / Severe Aplastic Anemia (SAA)1
1, 2CompletedTreatmentCNI Side Effects1
1, 2CompletedTreatmentCancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Renal Cancers1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias / Malignant Lymphomas1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1, 2CompletedTreatmentChronic Rejection of Lung Transplant / Decreased Immunologic Activity / Disorders Related to Lung Transplantation / Obliterative Bronchiolitis1
1, 2CompletedTreatmentCongenital Hypoplastic Anemia1
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 1 / Hypoglycemia1
1, 2CompletedTreatmentDry Eye Syndromes1
1, 2CompletedTreatmentLeukemias3
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1, 2CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1, 2CompletedTreatmentPsoriasis2
1, 2CompletedTreatmentRefractory Multiple Myeloma1
1, 2CompletedTreatmentRenal Cancers1
1, 2CompletedTreatmentSickle Cell Disorders1
1, 2CompletedTreatmentType 1 Mucopolysaccharidosis1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / CD45-Positive Neoplastic Cells Present / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome With Excess Blasts / Recurrent Adult Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia1
1, 2RecruitingTreatmentAnemias / Aplastic Anaemia (AA) / Neutropenias / Pancytopenia / Thrombocytopenias1
1, 2RecruitingTreatmentBeta Thalassemia-Major / Sickle Cell Disorders1
1, 2RecruitingTreatmentCongenital Hypoplastic Anemia1
1, 2RecruitingTreatmentHemophagocytic Lymphohistiocytosis (HLH)1
1, 2TerminatedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1, 2TerminatedTreatmentLeukemias1
1, 2Unknown StatusTreatmentAplastic Anaemia (AA)1
1, 2Unknown StatusTreatmentEnd-Stage Renal Disease (ESRD) / Renal Failure1
1, 2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
1, 2WithdrawnTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Nonmalignant Neoplasm1
1, 2WithdrawnTreatmentLeukemias1
2Active Not RecruitingTreatmentAccelerated Phase of Disease / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase of Disease / Recurrent Disease1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Graft Versus Host Disease (GVHD) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Malignant mast cell neoplasm / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAcute myeloid leukaemia (in remission) / Congenital Hypoplastic Anemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAdrenoleukodystrophy (ALD) / Alpha Mannosidosis / Aspartylglucosaminuria / Fucosidosis / Hunter Syndrome / Hurler's Syndrome / Krabbe's Disease / Metachromatic Leukodystrophy (MLD) / Mucopolysaccharidosis / Mucopolysaccharidosis VI / Peroxisomal Disorders / Sly Syndrome / Sphingolipidoses1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Relapsing Chronic Myelogenous Leukemia1
2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Previously Treated Myelodysplastic Syndromes / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Splenic Marginal Zone Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAnemias / Bone Marrow Transplant Failure / Myelodysplastic Syndromes (MDS) / Myeloid Leukemias / Myeloproliferative Disorders / Neural Tube Defects (NTDs)1
2Active Not RecruitingTreatmentAplastic Anaemia (AA) / Bone Marrow Failure / Haemoglobinuria / Hemolytic Anemia / Paroxysmal Hemoglobinuria / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Proteinuria / Thrombosis / Urination Disorders2
2Active Not RecruitingTreatmentAtypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Essential Thrombocythemia (ET) / Myeloproliferative Neoplasms / Paroxysmal Nocturnal Haemoglobinuria (PNH) / Polycythemia Vera (PV) / Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase / Primary Myelofibrosis / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
2Active Not RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / T-Cell Prolymphocytic Leukemia1
2Active Not RecruitingTreatmentChronic Granulomatous Disease (CGD)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma / T-Cell Large Granular Lymphocyte Leukemia1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Active Not RecruitingTreatmentImmunodeficiency Syndrome / Non-Cancer Diagnosis1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Plasma Cell Neoplasms / Renal Cancers1
2Active Not RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMyocardial Reperfusion Injury1
2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentRefractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentRetinoblastoma1
2CompletedPreventionAcute Kidney Injury (AKI)1
2CompletedPreventionChronic Lung Diseases1
2CompletedPreventionGraft Versus Host Disease (GVHD)1
2CompletedPreventionGraft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)1
2CompletedPreventionRejection, Transplant / Transplantation, Kidney / Transplantation, Renal1
2CompletedPreventionTransplantation, Kidney2
2CompletedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Intraocular Lymphoma / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Chronic Lymphocytic Leukemia / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Central Nervous System Hodgkin Lymphoma / Secondary Central Nervous System Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedSupportive CareAnemias / Leukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Myeloid Leukemia in Remission / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Philadelphia Chromosome Negative Chronic Myelogenous Leukemia / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Multiple Myeloma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndrome1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Peripheral T-Cell Lymphoma (PTCL)1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Childhood Acute Lymphoblastic Leukemia in Remission / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)1
2CompletedTreatmentAll / Aplastic Anaemia (AA) / CLL / CML Chronic Phase, Accelerated Phase, or Blast Crisis / Leukemia Acute Myeloid Leukemia (AML) / Multiple Myeloma (MM) / MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) / RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA / Smith-Magenis Syndrome1
2CompletedTreatmentAplastic Anaemia (AA)5
2CompletedTreatmentAplastic Anaemia (AA) / Congenital Hypoplastic Anemia1
2CompletedTreatmentAplastic Anaemia (AA) / Myelodysplastic Syndrome1
2CompletedTreatmentBeta-Thalassemia / Hematologic Diseases / Hematopoietic Stem Cell Transplantation (HSCT) / Sickle Cell Disorders1
2CompletedTreatmentBlood Cancers / CLL / Graft Versus Host Disease (GVHD) / Hodgkins Disease (HD) / Leukemias / Malignancies / NHL / Smith-Magenis Syndrome1
2CompletedTreatmentBlood Cancers / Leukemias1
2CompletedTreatmentBlood Cancers / Multiple Myeloma (MM)1
2CompletedTreatmentBlood and Marrow Transplant (BMT) / Multiple Myeloma (MM) / Transplantation, Autologous / Transplantation, Homologous1
2CompletedTreatmentBrittle Nail Syndrome1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Myocarditis1
2CompletedTreatmentCervical Cancers / Vaginal Cancers1
2CompletedTreatmentChronic Diseases / Leukaemia, Acute / Leukemias / Malignant Lymphomas / Myelodysplasia1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentCongenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Leukemias / Myelodysplastic Syndromes / Severe Congenital Neutropenia1
2CompletedTreatmentCongenital Hypoplastic Anemia / Hematologic Diseases1
2CompletedTreatmentConjunctivitis, Seasonal Allergic1
2CompletedTreatmentCytopaenia1
2CompletedTreatmentDry Eye Syndromes2
2CompletedTreatmentGiant Cell Myocarditis / Myocarditis1
2CompletedTreatmentGlomerulonephritis minimal lesion / Systemic Lupus Erythematosus (SLE)1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Thymic Carcinoma1
2CompletedTreatmentHansen's Disease3
2CompletedTreatmentHematologic Diseases / Myelodysplastic Syndromes1
2CompletedTreatmentHepatitis C, Chronic1
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2CompletedTreatmentImmunosuppresion / Neutropenias / Pancytopenia / Thrombocytopenias1
2CompletedTreatmentInterstitial Cystitis1
2CompletedTreatmentKeratoconjunctivitis Sicca1
2CompletedTreatmentKeratoconjunctivitis Sicca / Sjögren's Syndrome1
2CompletedTreatmentLeukemias7
2CompletedTreatmentLeukemias / Malignant Lymphomas2
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes2
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes5
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLiver Diseases / Transplantation, Liver1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentMild to Moderate Ulcerative Colitis1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentMyelodysplastic Syndrome3
2CompletedTreatmentOnychoclasis1
2CompletedTreatmentOpen Angle Glaucoma (OAG)1
2CompletedTreatmentPeriodontitis1
2CompletedTreatmentPterygium1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSevere Aplastic Anemia (SAA)1
2CompletedTreatmentTransplantation, Kidney3
2CompletedTreatmentTransplantation, Renal1
2Not Yet RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Not Yet RecruitingTreatmentLeukemia, Acute / Smith-Magenis Syndrome1
2Not Yet RecruitingTreatmentSevere Aplastic Anemia (SAA)1
2RecruitingPreventionAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Aggressive Non-Hodgkin Lymphoma / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Diffuse Large B -Cell Lymphoma / DS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Leukemia, Prolymphocytic / Loss of Chromosome 17p / Myelodysplastic/Myeloproliferative Neoplasms / Non-Hodgkin's Lymphoma (NHL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Aggressive Adult Non-Hodgkin Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Stage I Adult Hodgkin Lymphoma / Stage I Aggressive Adult Non-Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Diffuse Large B-Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Contiguous Adult Aggressive Non-Hodgkin Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Non-Contiguous Aggressive Adult Non-Hodgkin Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage II Small Lymphocytic Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Aggressive Adult Non-Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Diffuse Large B-Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Aggressive Adult Non-Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingPreventionGraft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute erythroid leukemia / Acute Lymphoblastic Leukemia in Remission / Acute Megakaryoblastic Leukemia / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Blasts Under 10 Percent of Bone Marrow Nucleated Cells / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Pancytopenia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Secondary Acute Myeloid Leukemia1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Complete Remission / Adult Acute Myeloid Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Aggressive Non-Hodgkin Lymphoma / Agnogenic Myeloid Metaplasia / B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1) / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Burkitt's Lymphoma / Childhood Acute Lymphoblastic Leukemia in Complete Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemia, Prolymphocytic / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome With Excess Blasts / Pancytopenia / Plasma Cell Myeloma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia With Excess Blasts1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Myelodysplastic Syndrome / Blasts Under 5 Percent of Bone Marrow Nucleated Cells / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Childhood Myelodysplastic Syndrome / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Myelodysplastic Syndrome With Excess Blasts-2 / RAEB-2 / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Anemia With Excess Blasts / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Hematopoietic Cell Transplantation Recipient / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Loss of Chromosome 17p / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Recurrent Waldenstrom Macroglobulinemia / T-cell chronic lymphocytic leukaemia1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Refractory Anemia / Smith-Magenis Syndrome1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia / Adult Diffuse Large B-Cell Lymphoma / Adult Myelodysplastic Syndrome / Adult Non-Hodgkin's Lymphoma / Aggressive Non-Hodgkin Lymphoma / Childhood Acute Lymphoblastic Leukemia / Childhood Acute Myeloid Leukemia / Childhood Diffuse Large B -Cell Lymphoma / Childhood Diffuse Large B-Cell Lymphoma / Childhood Myelodysplastic Syndrome / Childhood Non-Hodgkin's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Lymphocytic Leukemia in Remission / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Leukemia, Prolymphocytic / Mantle Cell Lymphoma (MCL) / Plasma Cell Myeloma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentAplastic Anaemia (AA)2
2RecruitingTreatmentAplastic Anaemia (AA) / Dyskeratosis Congenita / Hoyeraal Hreidarsson Syndrome / Revesz Syndrome1
2RecruitingTreatmentAplastic Anaemia (AA) / Hypoplastic Myelodysplastic Syndrome1
2RecruitingTreatmentAtopic Dermatitis (AD)1
2RecruitingTreatmentAutoimmune Diseases / Glomerular Diseases / Glomerulonephritis minimal lesion / Glomerulonephritis, Membranous / Proteinuria1
2RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas / Chronic Lymphocytic Leukaemia (CLL) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / T-Cell Non-Hodgkin Lymphoma1
2RecruitingTreatmentBone Marrow Transplant Failure / Cutaneous T-Cell Lymphoma (CTCL) / Lymphoma, T-Cell, Cutaneous / Mycoses / Non-Hodgkin's Lymphoma (NHL) / Sezary Syndrome1
2RecruitingTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndrome / De Novo Myelodysplastic Syndrome / Leukemias / Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
2RecruitingTreatmentDelayed Graft Function / Transplant, Kidney1
2RecruitingTreatmentDry Eye Syndrome (DES)1
2RecruitingTreatmentEpidermolysis Bullosa1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentLeukemias1
2RecruitingTreatmentNon-Malignant1
2RecruitingTreatmentPost-Transplant Lymphoproliferative Disorder / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
2RecruitingTreatmentRefractory Non-Hodgkin's lymphoma / Relapsed Non Hodgkin Lymphoma1
2SuspendedTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Malignant Lymphoma, Large Cell Type / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Follicular Lymphoma / Refractory Hodgkin Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Refractory Small Lymphocytic Lymphoma / T-Cell Non-Hodgkin Lymphoma1
2SuspendedTreatmentUnrecognized Condition: Mature B or T-cell Neoplasm1
2TerminatedPreventionCardiopulmonary Bypass / Coronary Artery Bypass Surgery1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentDry Eye Syndromes1
2TerminatedTreatmentEnd-Stage Renal Disease (ESRD)1
2TerminatedTreatmentLeukemia, Large Granular Lymphocytic / LGL Leukemia1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2TerminatedTreatmentMalignant Lymphomas2
2TerminatedTreatmentPediatric Liver Transplantation1
2TerminatedTreatmentRenal Cancers1
2Unknown StatusPreventionGraft Versus Host Disease (GVHD)1
2Unknown StatusTreatmentCyclosporin Overdose / Idiopathic Membranous Nephropathy / Proteinuria / Spontaneous Remission / Steroid Nephropathy1
2Unknown StatusTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Precancerous Conditions1
2Unknown StatusTreatmentHematopoietic/Lymphoid Cancer1
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentLeber's Hereditary Optic Neuropathy (LHON)1
2Unknown StatusTreatmentLeukemias1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentNonmalignant Neoplasm1
2Unknown StatusTreatmentRefractory Follicular Lymphoma1
2Unknown StatusTreatmentRenal Cancers2
2WithdrawnPreventionTransplantation, Kidney1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
2WithdrawnTreatmentLacrimation increased1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentNeuroblastomas1
2WithdrawnTreatmentPsoriasis1
2, 3Active Not RecruitingTreatmentChronic Graft Versus Host Disease1
2, 3Active Not RecruitingTreatmentIdiopathic Membranous Nephropathy1
2, 3CompletedNot AvailableConjunctivitis, Vernal1
2, 3CompletedPreventionGraft Versus Host Disease (GVHD)1
2, 3CompletedTreatmentFamilial Lipoprotein Lipase Deficiency1
2, 3CompletedTreatmentHTLV I Associated Myelopathies1
2, 3CompletedTreatmentHansen's Disease1
2, 3CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
2, 3CompletedTreatmentMalignant Lymphomas1
2, 3CompletedTreatmentVernal Keratoconjunctivitis1
2, 3Not Yet RecruitingTreatmentRecurrent Miscarriages1
2, 3RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2, 3RecruitingTreatmentDry Eye Syndrome (DES)1
2, 3RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2, 3Unknown StatusTreatmentChronic Graft Versus Host Disease1
2, 3Unknown StatusTreatmentFamilial Lipoprotein Lipase Deficiency1
2, 3Unknown StatusTreatmentOsteopetrosis1
2, 3WithdrawnTreatmentTransplantation, Kidney1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Aggressive Non-Hodgkin Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Hematopoietic and Lymphoid Cell Neoplasm / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Prolymphocytic / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Refractory Chronic Lymphocytic Leukemia / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Hodgkin Lymphoma / Small Lymphocytic Lymphoma (SLL) / T-cell chronic lymphocytic leukaemia / Waldenstrom's Macroglobulinemia (WM)1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukemia in Remission / Acute myeloid leukaemia (in remission) / Aggressive Non-Hodgkin Lymphoma / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Myelodysplastic/Myeloproliferative Neoplasms / Plasma Cell Myeloma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
3Active Not RecruitingTreatmentLymphohistiocytosis, Hemophagocytic1
3Active Not RecruitingTreatmentThrombotic Thrombocytopenic Purpura (TTP)1
3Active Not RecruitingTreatmentTransplantation, Kidney1
3CompletedNot AvailableDry Eye Syndromes2
3CompletedPreventionChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
3CompletedPreventionDe Novo Kidney Transplant Recipients / Transplantation, Renal1
3CompletedPreventionGraft Versus Host Disease (GVHD) / Survival1
3CompletedPreventionImmunosuppression / Obliterative Bronchiolitis1
3CompletedPreventionLung Transplant1
3CompletedPreventionPediatric Kidney Transplantation1
3CompletedPreventionTransplantation, Kidney1
3CompletedPreventionTransplantation, Renal1
3CompletedSupportive CareGraft Versus Host Disease (GVHD)1
3CompletedSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
3CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndrome / Natural Killer Cell Lymphoblastic Leukemia/Lymphoma1
3CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Myeloid Leukemia/Transient Myeloproliferative Disorder / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
3CompletedTreatmentAcute atopic conjunctivitis1
3CompletedTreatmentAortic Valvular Surgery1
3CompletedTreatmentAtopic Dermatitis (AD)1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentChronic Kidney Failure / Transplantation, Kidney1
3CompletedTreatmentChronic Plaque Psoriasis1
3CompletedTreatmentDry Eye Syndrome (DES)1
3CompletedTreatmentDry Eye Syndromes3
3CompletedTreatmentGlomerulosclerosis, Focal Segmental1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignant Lymphomas1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Renal Failure1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Transplantation, Kidney1
3CompletedTreatmentHeart Diseases / Heart Transplantation1
3CompletedTreatmentHeart Transplantation1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentKeratoconjunctivitis Sicca1
3CompletedTreatmentLeukemias1
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
3CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentModerate to Severe Dry Eye Syndrome1
3CompletedTreatmentMyelodysplastic Syndromes1
3CompletedTreatmentOrgan Transplantation, Renal Transplantation1
3CompletedTreatmentPsoriasis1
3CompletedTreatmentRejection, Transplant1
3CompletedTreatmentRejection, Transplant / Transplantation, Kidney1
3CompletedTreatmentRenal Interstitial Fibrosis1
3CompletedTreatmentST Elevation Acute Myocardial Infarction1
3CompletedTreatmentSevere Atopic Dermatitis2
3CompletedTreatmentSkin Cancers / Transplantation, Kidney1
3CompletedTreatmentTransplantation Infection1
3CompletedTreatmentTransplantation, Kidney3
3CompletedTreatmentTransplantation, Liver1
3CompletedTreatmentTransplantation, Renal3
3Not Yet RecruitingTreatmentMembranoproliferative Glomerulonephritis1
3Not Yet RecruitingTreatmentStevens Johnson Syndrome / Toxic Epidermal Necrolyses1
3RecruitingTreatmentBehçet's Disease / Uveitis1
3RecruitingTreatmentFailing Renal Allograft / Transplant, Kidney1
3RecruitingTreatmentGlomerulonephritis, Membranous1
3RecruitingTreatmentHand Eczema1
3RecruitingTreatmentST Elevation Acute Myocardial Infarction1
3RecruitingTreatmentSevere Aplastic Anemia (SAA)1
3TerminatedSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
3TerminatedTreatmentAnti-r-HuEpo Associated PRCA Subjects1
3TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection / Evidence of Liver Transplantation1
3TerminatedTreatmentEnd-Stage Renal Disease (ESRD) / Transplantation, Kidney1
3TerminatedTreatmentGraft Versus Host Disease (GVHD)1
3TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias / Myeloid Leukemias1
3TerminatedTreatmentLeukemias1
3TerminatedTreatmentTransplantation, Kidney1
3Unknown StatusTreatmentBehcet's Syndrome / Diffuse posterior uveitis / Panuveitis / Vasculitis Retinal1
3Unknown StatusTreatmentColorectal Cancers1
3Unknown StatusTreatmentDry Eye Syndromes1
3Unknown StatusTreatmentJuvenile Dermatomyositis1
3Unknown StatusTreatmentNonneoplastic Condition1
3WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 12
3WithdrawnTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas1
3WithdrawnTreatmentImmune Thrombocytopenia1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal1
4CompletedNot AvailableCataracts / Eye Dryness1
4CompletedNot AvailableEndothelial Graft Rejection1
4CompletedNot AvailableFunction of Renal Transplant1
4CompletedNot AvailablePterygia1
4CompletedBasic ScienceEnd Stage Renal Disease (ESRD)1
4CompletedDiagnosticHeart and Lung Transplant1
4CompletedPreventionDisorder Related to Cardiac Transplantation1
4CompletedPreventionTransplantation, Kidney1
4CompletedSupportive CareChronic Hepatitis C Infection / Renal Allograft1
4CompletedTreatmentAdult Primary Kidney Transplantation1
4CompletedTreatmentAqueous Deficient Dry Eye Disease / Evaporative Dry Eye Disease / Primary Sjogren's Syndrome / Secondary Sjogren's Syndrome1
4CompletedTreatmentChronic Hepatitis C Infection1
4CompletedTreatmentChronic Hepatitis C Infection / End Stage Liver Diseases / Transplantation, Liver1
4CompletedTreatmentChronic Hepatitis C Infection / Transplantation, Liver1
4CompletedTreatmentChronic Renal Allograft Failure / Transplantation, Renal1
4CompletedTreatmentComplications of Transplanted Organs and Tissue / Diabetes Mellitus Nos New Onset1
4CompletedTreatmentDiabetic Nephropathies / Transplant, Kidney / Type 2 Diabetes Mellitus1
4CompletedTreatmentDisease Severity / OSDI / Progression, Disease / Schirmers / Staining1
4CompletedTreatmentDry Eye Syndrome (DES) / Keratoconjunctivitis Sicca1
4CompletedTreatmentDry Eye Syndromes2
4CompletedTreatmentEnd Stage Renal Disease (ESRD) / Transplantation, Renal1
4CompletedTreatmentEye Dryness1
4CompletedTreatmentGraft Versus Host Disease (GVHD)1
4CompletedTreatmentGraft Versus Host Disease (GVHD) / Renal Failure1
4CompletedTreatmentHeart Transplantation1
4CompletedTreatmentInflammatory Reaction1
4CompletedTreatmentKidney Transplantation, Renal Transplantation1
4CompletedTreatmentMyelodysplastic Syndrome1
4CompletedTreatmentPlanned Kidney Transplantation1
4CompletedTreatmentPolyomavirus Infections1
4CompletedTreatmentPsoriasis2
4CompletedTreatmentRenal Failure Chronic1
4CompletedTreatmentRenal Function and Chronic Allograft Vasculopathy1
4CompletedTreatmentRenal Transplanted Recipients1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentRosaceas1
4CompletedTreatmentStevens Johnson Syndrome1
4CompletedTreatmentTransplantation, Kidney4
4CompletedTreatmentTransplantation, Liver2
4CompletedTreatmentTransplantation, Renal2
4CompletedTreatmentUveitis1
4Not Yet RecruitingTreatmentAplastic Anaemia (AA)1
4Not Yet RecruitingTreatmentDisorder Related to Renal Transplantation / Immunosuppression Related Infectious Disease / Virus Diseases1
4Not Yet RecruitingTreatmentSjögren's Syndrome1
4RecruitingPreventionAcute Graft Versus Host Disease1
4RecruitingPreventionBeta-Thalassemia Major1
4RecruitingTreatmentCorneal Inflammation1
4RecruitingTreatmentDisorder Related to Bone Marrow Transplantation / Leukemia Acute Myeloid Leukemia (AML)1
4RecruitingTreatmentSevere Aplastic Anemia (SAA)1
4TerminatedPreventionChronic Hepatitis C Infection / Transplantation, Liver1
4TerminatedPreventionHeart Transplantation / Renal Function Abnormal1
4TerminatedPreventionSkin Cancers / Transplantation, Kidney1
4TerminatedPreventionTransplantation, Renal1
4TerminatedTreatmentAtopic Dermatitis (AD)1
4TerminatedTreatmentCardiac Transplantation / Hypertensive1
4TerminatedTreatmentKidney Transplant Rejection1
4TerminatedTreatmentTransplantation, Renal1
4Unknown StatusPreventionChronic Allograft Nephropathy (CAN)1
4Unknown StatusPreventionDiabetes / Rejection, Transplant1
4Unknown StatusPreventionImmunosuppression / Transplantation, Kidney / Transplantations2
4Unknown StatusTreatmentDry Eye Syndromes / HIV Seropositivity1
4Unknown StatusTreatmentImmunosuppression / Interstitial Fibrosis (IF) / Kidney Failure,Chronic / Transplantations1
4Unknown StatusTreatmentImmunosuppression / Transplant, Kidney1
4Unknown StatusTreatmentPsoriasis1
4Unknown StatusTreatmentTransplantation, Renal1
4WithdrawnTreatmentCardiovascular Disease (CVD) / Cardiovascular Outcomes / Kidney Transplant Recipients / Transplantation, Kidney1
4WithdrawnTreatmentDry Eye Syndrome (DES)1
4WithdrawnTreatmentKidney Graft Dysfunction1
Not AvailableActive Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / B-Cell Chronic Lymphocytic Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Childhood Renal Cell Carcinoma / Chronic Phase Chronic Myelogenous Leukemia / Clear Cell Renal Cell Carcinoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Splenic Marginal Zone Lymphoma / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer / T-Cell Large Granular Lymphocyte Leukemia / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAcute Myeloid Leukemia/Transient Myeloproliferative Disorder / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Malignant mast cell neoplasm / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Multiple Myeloma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage II Multiple Myeloma / Stage III Multiple Myeloma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableAvailableNot AvailableComplete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly / DiGeorge's syndrome1
Not AvailableCompletedNot AvailableDiabetes, Diabetes Mellitus Type 1 / Islet Transplantation1
Not AvailableCompletedNot AvailableDry Eye Syndrome (DES)1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableKeratoconjunctivitis Sicca1
Not AvailableCompletedOtherHealthy Volunteers1
Not AvailableCompletedPreventionEye Dryness2
Not AvailableCompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableCompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Undifferentiated Leukemia (AUL) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Aggressive NK-cell Leukemia / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Primary CNS Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Essential Thrombocythemia (ET) / Extramedullary Plasmacytoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / HIV-associated Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Intraocular Lymphoma / Isolated Plasmacytoma of Bone / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Malignant mast cell neoplasm / Meningeal Chronic Myelogenous Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myeloid/NK-cell Acute Leukemia / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Central Nervous System Lymphoma (PCNSL) / Primary Myelofibrosis / Primary Systemic Amyloidosis / Progressive Hairy Cell Leukemia, Initial Treatment / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableCompletedTreatmentAtopic Dermatitis (AD)1
Not AvailableCompletedTreatmentAtopic Keratoconjunctivitis1
Not AvailableCompletedTreatmentChronic Allograft Nephropathy (CAN) / Transplantation, Kidney1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentContact Lens Wearers With Dry Eye Syndrome1
Not AvailableCompletedTreatmentDiabetes, Diabetes Mellitus Type 11
Not AvailableCompletedTreatmentGlaucoma1
Not AvailableCompletedTreatmentGranulomatous Disease, Chronic / Metabolism, Inborn Errors1
Not AvailableCompletedTreatmentHeart Transplantation2
Not AvailableCompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentLiving Donors / Transplantation, Kidney1
Not AvailableCompletedTreatmentLysosomal Storage Diseases / Peroxisomal Disorders1
Not AvailableCompletedTreatmentMyocarditis1
Not AvailableCompletedTreatmentTransplant, Kidney1
Not AvailableRecruitingOtherSevere Aplastic Anemia (SAA)1
Not AvailableRecruitingPreventionImmunosuppression / Renal Failure1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Myelogenous Leukemia (CML) / Lymphoid Malignancies / Lymphoma, Hodgkins / Myelodysplastic Syndromes / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Relapsed Chronic Lymphocytic Leukemia / Relapsed Non-Hodgkin's Lymphoma1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
Not AvailableRecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Agnogenic Myeloid Metaplasia / Burkitt's Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Follicular Lymphoma (FL) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Plasma Cell / Leukemia, Prolymphocytic / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Lymphoblastic / Lymphoma, Mantle-Cell / Lymphoplasmacytic Lymphoma / Marginal Zone B-Cell Lymphoma / Multiple Myeloma (MM) / Myelodysplasia / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL)1
Not AvailableRecruitingTreatmentAllografts / Transplantation, Lung1
Not AvailableRecruitingTreatmentChronic Myeloid Leukemia (CML) / Leukaemia, Acute / Myelodysplastic Syndrome1
Not AvailableRecruitingTreatmentChronic Myelomonocytic Leukemia-2 / High Grade Malignant Neoplasm / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts-2 / Myeloid Neoplasm / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentCorneal Graft Rejection1
Not AvailableTerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Lymphoma, Mantle-Cell / Multiple Myeloma (MM) / Myelodysplasia / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentBruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Sarcomas1
Not AvailableTerminatedTreatmentLeukemias / Malignant Lymphomas1
Not AvailableUnknown StatusNot AvailableAcquired Haemophilia1
Not AvailableUnknown StatusNot AvailableIdiopathic Membranous Nephropathy1
Not AvailableUnknown StatusNot AvailableKeratoconus1
Not AvailableUnknown StatusPreventionGraft Versus Host Disease (GVHD) / Hematopoietic Stem Cell Transplantation (HSCT)1
Not AvailableUnknown StatusSupportive CareGraft Versus Host Disease (GVHD) / Leukemias1
Not AvailableUnknown StatusTreatmentAnemia, Hemolytic, Autoimmune / Arthritis, Juvenile Rheumatoid / Autoimmune Thrombocytopenic Purpura / Churg-Strauss Syndrome (CSS) / Giant Cells Arteritis / Graft Versus Host Disease (GVHD) / Granulomatosis With Polyangiitis / Polyarteritis Nodosa / Pure Red Cell Aplasia / Purpura, Schoenlein-Henoch / Rheumatoid Arthritis / Systemic Lupus Erythematosus (SLE) / Takayasu's Disease / Vasculitis, Hypersensitivity1
Not AvailableUnknown StatusTreatmentAplastic Anaemia (AA) / Graft Versus Host Disease (GVHD)1
Not AvailableUnknown StatusTreatmentBlood and Marrow Transplant (BMT) / Graft Versus Host Disease (GVHD)1
Not AvailableUnknown StatusTreatmentChediak-Higashi Syndrome / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Lymphohistiocytosis, Hemophagocytic / Virus-Associated Hemophagocytic Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableUnknown StatusTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Pliva inc
  • Sandoz inc
  • Abbott laboratories
  • Novartis pharmaceuticals corp
  • Allergan inc
  • Bedford laboratories div ben venue laboratories inc
  • Pharmaforce inc
  • Novex pharma
  • Watson laboratories inc
  • Wockhardt eu operations (swiss) ag
Packagers
Dosage forms
FormRouteStrength
LiquidOphthalmic.0005 g/100mL
LiquidTopical.25 g/100mL
Capsule, gelatin coatedOral100 mg/1
Capsule, gelatin coatedOral25 mg/1
Injection, solutionIntravenous50 mg/mL
SolutionOral100 mg/mL
Capsule, liquid filledOral100 mg/1
Capsule, liquid filledOral25 mg/1
Capsule, liquid filledOral50 mg/1
CapsuleOral100 mg/1
CapsuleOral25 mg/1
CapsuleOral50 mg/1
CapsuleOral100 mg
CapsuleOral10 mg
CapsuleOral25 mg
CapsuleOral50 mg
SolutionOral100 mg
EmulsionOphthalmic.5 mg/mL
EmulsionOphthalmic0.05 %
InjectionIntravenous50 mg/mL
LiquidIntravenous50 mg
LiquidOral100 mg
Prices
Unit descriptionCostUnit
SandIMMUNE 100 mg/ml Solution 50ml Bottle499.62USD bottle
Neoral 100 mg/ml Solution 50ml Bottle346.14USD bottle
CycloSPORINE Modified 100 mg/ml Solution 50ml Bottle311.53USD bottle
SandIMMUNE 30 100 mg capsule Box308.69USD box
Restasis 30 0.05% Emulsion 1 Box = 30 Containers205.99USD box
Neoral 30 100 mg capsule Box190.54USD box
CycloSPORINE Modified 30 100 mg capsule Box171.48USD box
Gengraf 30 100 mg capsule Box159.94USD box
SandIMMUNE 30 25 mg capsule Box77.33USD box
Neoral 30 25 mg capsule Box47.69USD box
SandIMMUNE 50 mg/ml Solution 5ml Ampule46.38USD ampule
Gengraf 30 25 mg capsule Box42.99USD box
CycloSPORINE Modified 30 25 mg capsule Box42.9USD box
Cyclosporine a powder25.2USD g
Sandimmune 100 mg capsule9.89USD capsule
Sandimmune 50 mg/ml ampul7.71USD ml
Cyclosporine 100 mg capsule6.46USD capsule
Neoral 100 mg gelatn capsule6.11USD capsule
Cyclosporine 100 mg softgel5.5USD softgel capsule
Cyclosporine modif 100 mg softgel5.5USD softgel capsule
Cyclosporine modif 100 mg capsule5.49USD capsule
Cyclosporine 50 mg/ml amp5.45USD ml
Cyclosporine 50 mg/ml vial5.28USD ml
Gengraf 100 mg capsule5.28USD capsule
Restasis 0.05% eye emulsion4.49USD each
Cyclosporine 50 mg softgel2.74USD softgel capsule
Sandimmune 25 mg capsule2.48USD capsule
Cyclosporine 25 mg capsule1.56USD capsule
Neoral 25 mg gelatin capsule1.53USD capsule
Cyclosporine 25 mg softgel1.38USD softgel capsule
Gengraf 25 mg capsule1.32USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5985321No1994-09-262014-09-26Us
US4839342No1992-08-022009-08-02Us
CA2108018No2003-04-152012-04-16Canada
CA1332150No1994-09-272011-09-27Canada
US8633162No2004-08-272024-08-27Us
US8648048No2004-08-272024-08-27Us
US9248191No2004-08-272024-08-27Us
US8629111No2004-08-272024-08-27Us
US8642556No2004-08-272024-08-27Us
US8685930No2004-08-272024-08-27Us
US8561859No2012-04-162032-04-16Us
US9676525No2014-02-072034-02-07Us
US8292129No2011-02-252031-02-25Us
US9669974No2014-05-112034-05-11Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)148-151 °CNot Available
Caco2 permeability-6.05ADME Research, USCD
Predicted Properties
PropertyValueSource
logP3.64ChemAxon
pKa (Strongest Acidic)11.83ChemAxon
pKa (Strongest Basic)-2.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area278.8 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity327.14 m3·mol-1ChemAxon
Polarizability133.6 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8727
Blood Brain Barrier-0.9659
Caco-2 permeable-0.6994
P-glycoprotein substrateSubstrate0.8463
P-glycoprotein inhibitor IInhibitor0.8685
P-glycoprotein inhibitor IINon-inhibitor0.5992
Renal organic cation transporterNon-inhibitor0.9485
CYP450 2C9 substrateNon-substrate0.8628
CYP450 2D6 substrateNon-substrate0.8823
CYP450 3A4 substrateSubstrate0.6407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.923
CYP450 2D6 inhibitorNon-inhibitor0.9265
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.6112
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9968
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8948
BiodegradationNot ready biodegradable0.9244
Rat acute toxicity2.8788 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9815
hERG inhibition (predictor II)Non-inhibitor0.9214
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclosporins. These are cyclic depsipeptides containing the cyclosporin backbone.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Peptidomimetics
Sub Class
Peptoid-peptide hybrids
Direct Parent
Cyclosporins
Alternative Parents
Oligopeptides / Macrolactams / Alpha amino acids and derivatives / Tertiary carboxylic acid amides / Secondary carboxylic acid amides / Secondary alcohols / Lactams / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
Cyclosporin-backbone / Alpha-oligopeptide / Macrolactam / Alpha-amino acid or derivatives / Tertiary carboxylic acid amide / Carboxamide group / Lactam / Secondary alcohol / Secondary carboxylic acid amide / Carboxylic acid derivative
show 12 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
homodetic cyclic peptide (CHEBI:4031)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Not Available
Specific Function
Likely involved in the mobilization of calcium as a result of the TCR/CD3 complex interaction. Binds to cyclophilin B.
Gene Name
CAMLG
Uniprot ID
P49069
Uniprot Name
Calcium signal-modulating cyclophilin ligand
Molecular Weight
32952.255 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Bernasconi R, Solda T, Galli C, Pertel T, Luban J, Molinari M: Cyclosporine A-sensitive, cyclophilin B-dependent endoplasmic reticulum-associated degradation. PLoS One. 2010 Sep 28;5(9). pii: e13008. doi: 10.1371/journal.pone.0013008. [PubMed:20927389]
  4. Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3. [PubMed:20674565]
  5. Galat A, Bua J: Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cell Mol Life Sci. 2010 Oct;67(20):3467-88. doi: 10.1007/s00018-010-0437-0. Epub 2010 Jul 4. [PubMed:20602248]
  6. Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97. [PubMed:20637127]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Calcium ion binding
Specific Function
Regulatory subunit of calcineurin, a calcium-dependent, calmodulin stimulated protein phosphatase. Confers calcium sensitivity (By similarity).
Gene Name
PPP3R2
Uniprot ID
Q96LZ3
Uniprot Name
Calcineurin subunit B type 2
Molecular Weight
19533.065 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Yamashita H, Ito T, Kato H, Asai S, Tanaka H, Nagai H, Inagaki N: Comparison of the efficacy of tacrolimus and cyclosporine A in a murine model of dinitrofluorobenzene-induced atopic dermatitis. Eur J Pharmacol. 2010 Oct 25;645(1-3):171-6. doi: 10.1016/j.ejphar.2010.07.031. Epub 2010 Aug 3. [PubMed:20674565]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virion binding
Specific Function
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.
Gene Name
PPIA
Uniprot ID
P62937
Uniprot Name
Peptidyl-prolyl cis-trans isomerase A
Molecular Weight
18012.42 Da
References
  1. Keckesova Z, Ylinen LM, Towers GJ: Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol. 2006 May;80(10):4683-90. [PubMed:16641261]
  2. Patwardhan AM, Jeske NA, Price TJ, Gamper N, Akopian AN, Hargreaves KM: The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11393-8. Epub 2006 Jul 18. [PubMed:16849427]
  3. Redell JB, Zhao J, Dash PK: Acutely increased cyclophilin a expression after brain injury: a role in blood-brain barrier function and tissue preservation. J Neurosci Res. 2007 Jul;85(9):1980-8. [PubMed:17461417]
  4. Schaller T, Ylinen LM, Webb BL, Singh S, Towers GJ: Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J Virol. 2007 Sep;81(18):10055-63. Epub 2007 Jul 3. [PubMed:17609268]
  5. Lee J, Kim SS: Current implications of cyclophilins in human cancers. J Exp Clin Cancer Res. 2010 Jul 19;29:97. doi: 10.1186/1756-9966-29-97. [PubMed:20637127]
  6. Stegmann CM, Luhrmann R, Wahl MC: The crystal structure of PPIL1 bound to cyclosporine A suggests a binding mode for a linear epitope of the SKIP protein. PLoS One. 2010 Apr 2;5(4):e10013. doi: 10.1371/journal.pone.0010013. [PubMed:20368803]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Peptidyl-prolyl cis-trans isomerase activity
Specific Function
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Involved in regulation of the mitochondrial permeability trans...
Gene Name
PPIF
Uniprot ID
P30405
Uniprot Name
Peptidyl-prolyl cis-trans isomerase F, mitochondrial
Molecular Weight
22040.09 Da
References
  1. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984 Nov 2;226(4674):544-7. [PubMed:6238408]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
2. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
4. Cytochrome P450 2C19
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
6. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
7. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  2. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137]
  3. Tiberghien F, Kurome T, Takesako K, Didier A, Wenandy T, Loor F: Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter. J Med Chem. 2000 Jun 29;43(13):2547-56. [PubMed:10891114]
  4. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287]
  5. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  6. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143]
  7. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113]
  8. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945]
  9. Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71. [PubMed:12604693]
  10. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153]
  11. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  12. Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ: Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol. 2003 Sep;285(3):C584-91. Epub 2003 Apr 30. [PubMed:12724138]
  13. Hamada A, Miyano H, Watanabe H, Saito H: Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003 Nov;307(2):824-8. Epub 2003 Sep 15. [PubMed:12975485]
  14. Corea G, Fattorusso E, Lanzotti V, Taglialatela-Scafati O, Appendino G, Ballero M, Simon PN, Dumontet C, Di Pietro A: Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L. Bioorg Med Chem. 2003 Nov 17;11(23):5221-7. [PubMed:14604686]
  15. Rao US, Scarborough GA: Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol. 1994 Apr;45(4):773-6. [PubMed:7514263]
  16. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. [PubMed:8960059]
  17. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. [PubMed:9205004]
  18. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363]
  19. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409]
  20. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K: Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res. 1998 Nov;89(11):1220-8. [PubMed:9914792]
  21. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141]
  22. Wigler PW: PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts. Biochem Biophys Res Commun. 1999 Apr 13;257(2):410-3. [PubMed:10198227]
  23. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH: Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther. 2000 Jan;292(1):310-8. [PubMed:10604964]
  24. Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T: Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9. [PubMed:14744620]
  25. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D: The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release. 2004 Mar 24;95(3):447-53. [PubMed:15023456]
  26. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753]
  27. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  28. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
  29. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. [PubMed:19530439]
  30. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690]
  31. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  32. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
  33. Seeballuck F, Ashford MB, O'Driscoll CM: The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res. 2003 Jul;20(7):1085-92. [PubMed:12880295]
  34. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  35. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993 Mar 25;268(9):6077-80. [PubMed:7681059]
  36. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C: Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol. 1996 Aug;118(7):1841-7. [PubMed:8842452]
  37. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997 Sep;62(3):248-60. [PubMed:9333100]
  38. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85. [PubMed:10227700]
  39. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
Details
3. Bile salt export pump
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ: The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology. 2002 Nov;123(5):1649-58. [PubMed:12404239]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759]
  3. Noe J, Hagenbuch B, Meier PJ, St-Pierre MV: Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. Hepatology. 2001 May;33(5):1223-31. [PubMed:11343252]
  4. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675]
  5. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ: Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology. 2000 Feb;118(2):422-30. [PubMed:10648470]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Pec MK, Aguirre A, Fernandez JJ, Souto ML, Dorta JF, Villar J: Dehydrothyrsiferol does not modulate multidrug resistance-associated protein 1 resistance: a functional screening system for MRP1 substrates. Int J Mol Med. 2002 Nov;10(5):605-8. [PubMed:12373300]
  2. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994 Nov 11;269(45):27807-10. [PubMed:7961706]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Bile acid:sodium symporter activity
Specific Function
Plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine. Plays a key role in cholesterol metabolism.
Gene Name
SLC10A2
Uniprot ID
Q12908
Uniprot Name
Ileal sodium/bile acid cotransporter
Molecular Weight
37713.405 Da
References
  1. Craddock AL, Love MW, Daniel RW, Kirby LC, Walters HC, Wong MH, Dawson PA: Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. [PubMed:9458785]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Virus receptor activity
Specific Function
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presenc...
Gene Name
SLC10A1
Uniprot ID
Q14973
Uniprot Name
Sodium/bile acid cotransporter
Molecular Weight
38118.64 Da
References
  1. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Sweet DH, Wolff NA, Pritchard JB: Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem. 1997 Nov 28;272(48):30088-95. [PubMed:9374486]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946]
  2. Hong J, Lambert JD, Lee SH, Sinko PJ, Yang CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res Commun. 2003 Oct 10;310(1):222-7. [PubMed:14511674]
  3. Kamisako T, Leier I, Cui Y, Konig J, Buchholz U, Hummel-Eisenbeiss J, Keppler D: Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90. [PubMed:10421658]
  4. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI: Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol. 1999 Dec;56(6):1219-28. [PubMed:10570049]
  5. Horikawa M, Kato Y, Tyson CA, Sugiyama Y: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet. 2002;17(1):23-33. [PubMed:15618649]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595]
  2. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 2003 Feb;304(2):610-6. [PubMed:12538813]
  3. Nozawa T, Tamai I, Sai Y, Nezu J, Tsuji A: Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin. J Pharm Pharmacol. 2003 Jul;55(7):1013-20. [PubMed:12906759]
  4. Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol. 2003 Nov;368(5):415-20. Epub 2003 Oct 3. [PubMed:14530907]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34